

# BMJ Open

## The General Weakness Syndrome Therapy (GymNAST) study: protocol for a cohort study on recovery on walking function.

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-006168
Article Type:	Protocol
Date Submitted by the Author:	22-Jul-2014
Complete List of Authors:	Mehrholz, Jan; Technische Universität Dresden, Department of Public Health, Medizinische Fakultät ‚Carl Gustav Carus‘ Mückel, Simone; Private Europäische Medizinische Akademie der Klinik Bavaria in Kreischa, Wissenschaftliches Institut Oehmichen, Frank; Klinik Bavaria Kreischa, Fach und Privatkrankenhaus Pohl, Marcus; Klinik Bavaria Kreischa, Fach und Privatkrankenhaus
<b>Primary Subject Heading</b>:	Intensive care
Secondary Subject Heading:	Evidence based practice, Rehabilitation medicine
Keywords:	Adult intensive & critical care < ANAESTHETICS, REHABILITATION MEDICINE, Adult neurology < NEUROLOGY

SCHOLARONE™  
Manuscripts

1  
2  
3 **The General Weakness Syndrome Therapy (GymNAST) study: protocol for a cohort**  
4 **study on recovery on walking function.**  
5

6  
7 Jan Mehrholz<sup>1,3\*</sup>, Simone Mückel<sup>1</sup>, Frank Oehmichen<sup>2</sup> and Marcus Pohl<sup>2</sup>  
8

9  
10 <sup>1</sup> *Wissenschaftliches Institut, Private Europäische Medizinische Akademie der Klinik Bavaria*  
11 *in Kreischa, An der Wolfsschlucht 1-2, 01731 Kreischa, Germany*  
12

13  
14 <sup>2</sup> *Fach und Privatkrankenhaus, Klinik Bavaria in Kreischa, An der Wolfsschlucht 1-2, 01731*  
15 *Kreischa, Germany*  
16

17  
18 <sup>3</sup> *Department of Public Health, Medizinische Fakultät, Carl Gustav Carus, Technische*  
19 *Universität Dresden, Germany*  
20

21  
22 **\*Corresponding author**  
23

24 Prof. Dr. Jan Mehrholz, Wissenschaftliches Institut, Private Europäische Medizinische  
25 Akademie der Klinik Bavaria in Kreischa GmbH, An der Wolfsschlucht 1-2, 01731 Kreischa,  
26 Germany  
27  
28

29  
30 Tel: ++49 35206 62054  
31

32  
33 Fax: ++49 35206 63517  
34

35 [jan.mehrholz@klinik-bavaria.de](mailto:jan.mehrholz@klinik-bavaria.de)  
36  
37

38  
39  
40 Short title: Study protocol: General Weakness Syndrome Therapy  
41

42  
43 Keywords: intensive care - rehabilitation - walking - muscle weakness  
44

45  
46 Word count: 4 267  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

Introduction: Critical illness myopathy (CIM) and polyneuropathy (CIP) are common complications of critical illness that frequently occur together. Both cause so called intensive-care-unit-acquired (ICU)-acquired muscle weakness. This weakness of limb muscles increases morbidity and delay rehabilitation and recovery of walking ability. Although full recovery has been reported people with severe weakness may take months to improve walking. Focused physical rehabilitation of people with ICU-acquired muscle weakness is therefore of great importance.

However, although physical rehabilitation is common, detailed knowledge about the pattern and the time course of recovery of walking function are not well understood.

Therefore the aim of the General Weakness Syndrome Therapy (GymNAST) study is to describe the time course of recovery of walking function and other activities of daily living in these patients.

Methods and analysis: We conduct a prospective cohort study of people with ICU-acquired muscle weakness with defined diagnosis of CIM or CIP.

Based on our sample size calculation, approximately 150 patients will be recruited from the intensive care unit of our hospital in Germany. Amount and content of physical rehabilitation, clinical tests e.g. muscle strength and motor function and neuropsychological assessments will be used as independent variables. The primary outcomes will include recovery of walking function and mobility. Secondary outcomes will include global motor function, activities in daily life and participation.

Ethics and dissemination: The study is being carried out in agreement with the Declaration of Helsinki and conducted with the approval of the local medical Ethics Committee (Landesärztekammer Sachsen, Germany, reference number EK-BR-32/13-1) and with the understanding and written consent of each patient's guardian.

The results of this study will be published in peer-reviewed journals and disseminated to the medical society and general public.

## Article Summary

### Article focus:

The aim of the General Weakness Syndrome Therapy (GymNAST) study is to determine the time course of recovery of walking function, to describe the detailed content of physical rehabilitation and also to describe possible risk factors and chances for recovery of walking function in the first year after ICU-acquired muscle weakness.

### Key messages:

This study will determine how people with ICU-acquired muscle weakness are related to clinical characteristics and describe the time course of motor and cognitive performance and activities of daily life.

The results will be of interest of clinicians working with critical ill patients and will give insights into the black box of rehabilitation and its impact on recovery of ICU-acquired muscle weakness due to CIM/CIP. The results of this study may therefore inform patients and their caregivers, therapists working in rehabilitation to choose the most appropriate treatment, and to develop adapted rehab programs.

### Strengths and limitations:

The strength of this study is that it is one of the first prospective cohort studies in the first year of ICU-acquired muscle weakness with daily documentation of physical rehabilitation and walking function. Multiple repeated assessments, with a wide range of clinical measures will be done. Such a measurement design has several advantages compared to other prognostic studies done so far using just two measurements in time. Our longitudinal repeated measure design may provide further insights into dynamics of recovery of walking function and other activities over the first year of people with ICU-acquired muscle weakness.

One limitation could be that most severe affected patients have to be excluded in this study. This may reduce the generalisability of the results to the whole population critical ill patients. Another limitation might be that no objective measures for muscle weakness such as electromyography or magnetic resonance tomography will be used.

## Introduction

Critical illness myopathy (CIM) and polyneuropathy (CIP) are common complications of critical illness that frequently occur together. Both cause so called intensive-care-unit-acquired (ICU)-acquired muscle weakness. According to Norton-Craft this weakness is characterized by a profound weakness that is greater than might be expected to result from prolonged bed rest [1]. The weakness of limb muscles limits significantly activities and assistance for basic activities such as sit-to stand or sitting and standing is oftentimes required [2-4]. This increases morbidity and delays rehabilitation and recovery of walking [5 6]. Although full recovery has been reported in approximately 50% of people with ICU-acquired muscle weakness, improvement is related to the severity of the condition e.g. people with severe weakness may take months to improve, or even remain severely affected [7]. Focused physical rehabilitation of people with ICU-acquired muscle weakness is therefore of great importance. There is practical evidence that physical rehabilitation of patients can be implemented with few adverse effects [1]. In recent years appropriate assessments were developed and description of suitable physical intervention strategies were described in the literature [1 8-11].

However, detailed knowledge about the time course of recovery of walking and other activities, their risk factors and chances for good recovery such are not well described or understood. Furthermore it lacks on detailed description of physical rehabilitation and on a repeated measure cohort study in the first year of people with ICU-acquired muscle weakness. Such a design would give better insights in to the time course of recovery of walking function and activities of these patients.

Therefore the aim of the General Weakness Syndrome Therapy (GymNAST) study is to describe and to identify time course and the pattern of recovery of walking, motor functions and of activities of daily living in these patients. Other aims are to describe the detailed content of physical rehabilitation and to develop a multivariate model of risk factors for recovery of walking function in the first year of ICU-acquired muscle weakness.

Here we describe the design and protocol of the GymNAST study, which is an appropriate large prospective cohort study of critical ill people with ICU-acquired muscle weakness including a detailed description of physical rehabilitation contents. This study will help to understand the time course and pattern of recovery of walking function and of activities of

1  
2  
3 daily live. Furthermore a multivariate model for recovery of walking ability will be  
4 developed.  
5

## 6 7 **Methods and analysis**

### 8 9 Study objectives

10  
11 The primary objective of the GymNAST study is to assess the time course of regaining  
12 walking and sit to stand ability as important activities of daily live  
13

14  
15 Secondary objectives are to:

- 16  
17 • describe the concomitant physical rehabilitation therapies
- 18  
19 • describe the clinical course of recovery using standardized outcome measures and their  
20 results
- 21  
22 • identify a prognostic model for regain walking and sit to stand abilities  
23  
24  
25  
26  
27

### 28 29 Design

30  
31 We conduct a prospective cohort study of people with ICU-acquired muscle weakness and  
32 defined diagnosis of CIM/CIP. We started in 2013 and the final assessments including follow  
33 up will be made in 2015.  
34  
35

36  
37 Based on our sample size calculation [12 13], approximately 150 patients will be recruited  
38 from a intensive care unit of our hospital in Germany [14] over the time course of three years.  
39  
40 In a first cross sectional pilot study in our hospital we found a point prevalence of 88 patients  
41 with defined diagnosis of CIM/CIP and ICU-acquired muscle weakness per month [15].  
42  
43 Therefore, based on this pilot study it seems to be realistically to reach the anticipated sample  
44 size in our cohort study within three years of recruitment.  
45  
46  
47

### 48 49 Study population

50  
51 Patients with ICU-acquired muscle weakness and defined diagnosis of CIM/CIP will be  
52 recruited consecutively from the intensive care units of our acute care, weaning and early  
53 rehabilitation centers of Klinik Bavaria Kreischa in Germany.  
54  
55

### 56 57 Inclusion criteria

- patient is chronic critical ill
- defined diagnosis of Critical illness myopathy (CIM) and polyneuropathy (CIP) [16 17]
- muscle weakness defined as a Medical Research Council (MRC) sum score of less than 48 points [1]
- more than 18 years old
- Richmond Agitation Sedation Scale (RASS) score from -1 to 2 [18]
- written informed consent of the patient or his legal guardian

#### Exclusion criteria

- Patients receiving palliative care
- Co-morbidities of the trunk or the lower limbs interfering with upright posture and walking function (e.g. Amputation or fracture of lower limb)
- Other neuromuscular or neurological disease (e.g. Guillain-Barré Syndrom, Stroke)
- severe physical co-morbidity before becoming critical ill (e.g, frailty due to neurological conditions)

#### Procedure

Eligible patients will be screened and afterwards will get oral and written information about the study from their treating physician or researcher. After written informed consent the demographic and clinical characteristics will be measured (baseline assessment T0). Patients will then be measured every two weeks after baseline up to 20 weeks (week two (T1), week four (T2), week six (T3), week eight (T4) week ten (T5) and so on until week twenty (T10)). Two follow ups are planned: FU1 after six month and FU2 after one year after study entry. For follow-up assessments (FU1 and FU2), patients and their guardians will be informed and invited by letter and telephone to participate.

The amount and the content of physical rehabilitation, activities of daily life such as the ability to walk will be documented every day by physiotherapists and occupational therapist using predefined sheets [15]. All assessments and standardized measures will be administered

1  
2  
3 by trained and experienced assessors or therapists in the hospital and/or inpatient  
4 rehabilitation, at home or residence facility.  
5  
6

### 7 Measures and Outcomes

8  
9 Primary outcomes of the GYMNAST study are walking ability and ability to stand up alone.  
10

11 To measure walking ability the Functional Ambulation Categories (FAC) is used [19]. The  
12 ability to stand up alone will be measured by the ability to stand up from a chair  
13 independently, STS (standardised chair height is defined with 120% of knee height).  
14  
15  
16

17 Secondary outcomes includes  
18

- 19
- 20 • Richmond Agitation-Sedation Scale (RASS) [18]
- 21
- 22 • activities measured with the Barthel Index (BI; 10 items) [20]
- 23
- 24 • muscle strength of the upper (shoulder, elbow and wrist) and lower limb (hip, knee  
25 and ankle) using the Medical Research Council (MRC) [1 21]
- 26
- 27 • grip strength [22 23]
- 28
- 29 • Functional Status Score for the Intensive Care Unit Scored (FSS-ICU) [24]
- 30
- 31 • Physical Function –ICU Test (PFIT) [25] and Physical Function –ICU Test- Scored  
32 (PFIT-S) [26]
- 33
- 34 • Pain using a visual analogue scale
- 35
- 36 • Lateral and frontal sit and stance balance (functional reach) [27 28]
- 37
- 38 • cognitive measures (Montreal Cognitive Assessment (MoCA) [29] and clock drawing  
39 test (CDT) [30]
- 40
- 41 • walking ability (FAC) [31], walking speed and endurance [5 6]
- 42
- 43 • quality of life (EQ-5D) [32]
- 44
- 45 • participation (Reintegration to Normal Living, RNL-Index) [33 34]
- 46
- 47 • fitness and mobility (PASIPD) [35 36]
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60



1  
2  
3 All measures chosen are frequently used in research and/or daily clinical practice dealing with  
4 the above described patients.  
5

6  
7 The primary outcome variables FAC and STS will be measured daily with standardized sheets  
8 for this purpose.  
9

10  
11 At baseline assessment (T0) and then every two weeks until twenty weeks after baseline  
12 (T10) we will assess RASS, BI, muscle strength of the upper and lower limb (MRC), grip  
13 strength, FSS-ICU, PFIT and PFIT-S, pain, functional reach, cognitive measures, walking  
14 speed and endurance.  
15  
16

17  
18 At follow ups FU1 after six month and FU2 after one year after study entry we will measure  
19 the EQ-5D, the RNL-Index and PASIPD. Additionally we will be gathering detailed survival  
20 data.  
21  
22

23  
24 Tables 1 gives a detailed overview of the variables used at each time point of study.  
25  
26

### 27 28 29 Possible clinical prognostic factors 30

31  
32 Depending on the primary outcomes (walking ability and activities), a range of potentially  
33 prognostic factors will be taken into account. These factors include: demographic variables  
34 (such as age, sex), clinical variables (such as FSS-ICU, PFIT-S) and medical characteristics  
35 (such as diagnosis, duration of illness).  
36  
37  
38

### 39 40 41 Planned statistical analyses 42

43  
44 We will use descriptive analyses, e.g. means and standard deviations of the continuous  
45 variables and frequencies and proportions of categorical variables as appropriate [37]. We will  
46 explain differences across the time points (T1–T10 and FU1 - FU2) descriptively and with  
47 appropriate inference statistics use parametric and non-parametric tests as appropriate e.g.  
48 repeated measures analysis of variance [37]. The global alpha level will be set at 0.05.  
49  
50  
51

52  
53 Time to regain walking ability and time to stand up from a chair independently will be the  
54 main end point for this analysis. The following factors will be analyzed for their association  
55 with these endpoints:  
56  
57

- 58 • demographic variables (such as age and sex),  
59  
60

- clinical variables (such as muscle strength, FSS-ICU, PFIT-S) and
- medical characteristics (such as diagnosis and duration of illness)

The probability in regaining walking ability and sit to stand ability will be calculated with the method of Kaplan and Meier [38]. Cox regression analysis will be used to estimate relative hazard rates and to test for differences in variables or trends in subgroups of each factor [39]. A stepwise multivariable Cox regression analysis will be applied with a variable selection [39-40].

Time to event or censoring will be defined as time difference between study entry (T0) and date of reaching a FAC score equal to 3, or the possible censoring dates of discharge or dead, respectively. Possible prognostic factors from demographic, clinical and medical variables will be selected for a multivariable model based on clinical and statistical significance [41-43]. The final model selection will be performed based on clinical decision, together with Akaike's information criterion (AIC) and the Bayesian information criterion (BIC) [40]. Aim of our analysis is to *explain* the dependent variable (regaining walking function) by a multivariate Cox proportional hazard model with not too many variables.

To prevent overfitting, only variables with clinically important *and* statistically significant bivariate association with our endpoint will be included in the final model [40].

The effects of prognostic factors in the final model will be expressed as hazard ratios (HR) with 95% confidence intervals (CI) after a graphical assessment of proportionality of hazards.

We will use SAS/STAT 9.3 for all statistical procedures (SAS Institute Inc., Cary, NC, USA). The proportional hazards assumption will be tested with the implemented function (proc phreg).

## Results

We will describe the demographic and clinical characteristics at each of the individual time points (T1–T10 and FU1 - FU2) descriptively. We will describe the probability in regaining walking ability and other activities with the method of Kaplan and Meier. We will present the final statistical multivariate model for regaining walking ability.

## Sample size and power calculation

1  
2  
3 The sample size needed in the GymNAST study is calculated using the method for one of the  
4 most cited recommendation for prognostic research: the ‘rule of ten events per variable  
5 (EPV)’ [12 13 43]. Based on our sample size calculation using the EPV-approach  
6 approximately 150 patients will be recruited from the intensive care unit of our long term  
7 intensive care hospital in Germany [14]. We anticipate reaching this study size over the time  
8 course of three years. Our confidence results from a cross-sectional study. We found a point  
9 prevalence of 88 patients per month of people with ICU-acquired muscle weakness and  
10 defined diagnosis of CIM/CIP in our intensive care units [15]. Therefore, based on this pilot  
11 study it seems to be a realistically to reach the estimated sample size in our cohort study  
12 within three years of recruitment.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

## 23 **Ethics and Dissemination**

### 24 Ethical considerations

25  
26  
27 The GymNAST study will be conducted in accordance with the ‘Helsinki Declaration’. The  
28 study is non-invasive, imposes no risk on patients, seems to have enough power to detect  
29 meaningful determinants and our protocol has been approved by the medical ethical  
30 committees. Furthermore, written informed consent is obtained from all participants or if  
31 necessary from its legal guardian. The study will be registered before publication.  
32  
33  
34  
35  
36

### 37 Dissemination

38  
39 The results obtained will be disseminated to the scientific, medical and general public by  
40 publication in national and international peer-reviewed journals, as well as by presentations in  
41 conferences and meetings with clinicians dealing with patients with ICU-acquired muscle  
42 weakness syndrome.  
43  
44  
45  
46  
47  
48

## 49 **Discussion**

50  
51 The GymNAST study will be one of the first studies with rigorous repeated measures over the  
52 time course of one year with daily documentation of rehabilitation therapies of people with  
53 ICU-acquired muscle weakness. Also a wide range of functional variables to describe the  
54 pattern of regaining of walking is used.  
55  
56  
57  
58  
59  
60

1  
2  
3 Until now many prognostic studies including people with ICU-acquired muscle weakness  
4 used rather a traditional prognostic design using a baseline test and compared with ICU  
5 discharge and follow-ups [5 25 26] and only some studies measures continuously over time  
6 [44]. However, instead of comparing two or more measurements of the patient's performance  
7 it seems to be more informative to analyze the dynamic recovery systematically using equal  
8 time intervals over an appropriate time period e.g. with daily assessments of walking function  
9 and with daily description of physical rehabilitation over months. This might provide a more  
10 detailed understanding of the pattern and the dynamics of recovery of walking function, and  
11 allows a better understanding of changes in clinical characteristics and the applied  
12 rehabilitation therapies.  
13  
14  
15  
16  
17  
18  
19

20 Also, detailed knowledge about the time course of recovery of walking ability, their risks and  
21 chances (e.g. clinical and therapeutic determinants) are still not very well understood. The  
22 present study documents clinical determinants at equal time intervals (every two weeks) and  
23 will document therapeutic determinants daily.  
24  
25  
26  
27

28 Strong aspects of GymNAST are therefore its prospective design with multiple repeated  
29 assessments during the first year after illness using equal time intervals of people with ICU-  
30 acquired muscle weakness. The present study might therefore provide new and more detailed  
31 information about the pattern of walking recovery and the physical rehabilitation content of  
32 people with ICU-acquired muscle weakness.  
33  
34  
35  
36

37 A potential limitation of the study is that the most seriously affected patients might be unable  
38 to participate, thereby reducing the possibility to generalize the results to the whole critical ill  
39 population. Another limitation might be that no objective measures for muscle weakness such  
40 as electromyography or magnetic resonance tomography will be used.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Authors' contributions:**

J.M., S.M, FO and M.P. planned the study. F.O. and M.P. contributed to the procurement of funding. J.M., S.M, and M.P. developed the protocol. All authors contributed to and checked the final draft of the manuscript.

**Funding statement:**

This study is financially supported by the Centre of Research from Klinik Bavaria, Kreischa, Germany and by the Department of Public Health, Medizinische Fakultät ,Carl Gustav Carus‘ , Technische Universität Dresden, Germany

**Competing interests statement:**

None declared

**Literatur**

1. Nordon-Craft A, Moss M, Quan D, Schenkman M. Intensive Care Unit-Acquired Weakness. *Phys Ther* 2012;92(12):1494-506.
2. Fan E. Critical illness neuromyopathy and the role of physical therapy and rehabilitation in critically ill patients. *Respir Care* 2012;57(6):933-44; discussion 944-6.
3. Herridge MS. The challenge of designing a post-critical illness rehabilitation intervention. *Crit Care* 2011;15(5):1002.
4. Ohtake PJ, Strasser DC, Needham DM. Rehabilitation for people with critical illness: taking the next steps. *Physical Therapy* 2012;92(12):1484-8.
5. Herridge MS, Cheung AM, Tansey CM, Matte-Martyn A, Diaz-Granados N, Al-Saidi F, et al. One-year outcomes in survivors of the acute respiratory distress syndrome. *N Engl J Med* 2003;348(8):683-93.
6. Herridge MS, Tansey CM, Matte A, Tomlinson G, Diaz-Granados N, Cooper A, et al. Functional disability 5 years after acute respiratory distress syndrome. *N Engl J Med* 2011;364(14):1293-304.
7. Hermans G, De Jonghe B, Bruyninckx F, Van den Berghe G. Clinical review: critical illness polyneuropathy and myopathy. *Critical Care*, 2008:238.
8. Denehy L, Berney S, Skinner E, Edbrook L, Warrillow S, Hawthorne G, et al. Evaluation of Exercise Rehabilitation for Survivors of Intensive Care: Protocol for Single Blind Randomised Controlled Trial. *The Open Critical Care Medicine Journal* 2008;1:39-47.
9. Denehy L, Berney S, Skinner E, Edbrooke L, Warrillow S, Hawthorne G, et al. Evaluation of exercise rehabilitation for survivors of intensive care: protocol for single blind randomised controlled trial. *Open Critical Care Medicine Journal*, 2008:39-47.
10. Denehy L, Skinner EH, Edbrooke L, Haines K, Warrillow S, Hawthorne G, et al. Exercise rehabilitation for patients with critical illness: a randomized controlled trial with 12 months follow up. *Crit Care* 2013;17(4):R156.
11. Nordon-Craft A, Schenkman M, Ridgeway K, Benson A, Moss M. Physical therapy management and patient outcomes following ICU-acquired weakness: a case series. *J Neurol Phys Ther* 2011;35(3):133-40.
12. Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. *J Clin Epidemiol* 1995;48(12):1503-10.

13. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. *Am J Epidemiol* 2007;165(6):710-8.
14. Mallett S, Royston P, Dutton S, Waters R, Altman DG. Reporting methods in studies developing prognostic models in cancer: a review. *BMC Med* 2010;8:20.
15. Mückel S, Mehrholz K, Mehrholz J, Pohl M. Treatment approaches of patients with ICU acquired weakness [Behandlungsansätze bei Patienten mit auf der Intensivstation erworbenen Schwächesyndrom]. *Neuroreha* 2013;5(1):40-43.
16. Latronico N, Rasulo FA. Presentation and management of ICU myopathy and neuropathy. *Curr Opin Crit Care* 2010;16(2):123-7.
17. Latronico N, Bolton C. Critical illness polyneuropathy and myopathy: a major cause of muscle weakness and paralysis. *Lancet Neurology* 2011;10(10):931-41.
18. Sessler CN, Gosnell MS, Grap MJ, Brophy GM, O'Neal PV, Keane KA, et al. The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients. *Am J Respir Crit Care Med* 2002;166(10):1338-44.
19. Holden MK, Gill KM, Magliozzi MR. Gait assessment for neurologically impaired patients. Standards for outcome assessment. *Phys Ther* 1986;66(10):1530-9.
20. Mahoney FI, Barthel DW. Functional Evaluation: The Barthel Index. *Md State Med J* 1965;14:61-5.
21. Kleyweg RP, van der Meche FG, Schmitz PI. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barre syndrome. *Muscle Nerve* 1991;14(11):1103-9.
22. Mathiowetz V, Weber K, Volland G, Kashman N. Reliability and validity of grip and pinch strength evaluations. *J Hand Surg Am* 1984;9(2):222-6.
23. Mathiowetz V, Kashman N, Volland G, Weber K, Dowe M, Rogers S. Grip and pinch strength: normative data for adults. *Arch Phys Med Rehabil* 1985;66(2):69-74.
24. Zanni JM, Korupolu R, Fan E, Pradhan P, Janjua K, Palmer JB, et al. Rehabilitation therapy and outcomes in acute respiratory failure: an observational pilot project. *J Crit Care* 2010;25(2):254-62.
25. Nordon-Craft A, Schenkman M, Edbrooke L, Malone DJ, Moss M, Denehy L. The Physical Function Intensive Care Test: Implementation in Survivors of Critical Illness. *Phys Ther* 2014.
26. Denehy L, de Morton N, Skinner E, Edbrooke L, Haines K, Warrillow S, et al. A Physical Function Test for Use in the Intensive Care Unit: Validity, Responsiveness, and

- 1  
2  
3 Predictive Utility of the Physical Function in Intensive Care Test (Scored). *Phys Ther*  
4 2013;93(12):1636-45.  
5  
6 27. Weiner DK, Duncan PW, Chandler J, Studenski SA. Functional reach: a marker of  
7 physical frailty. *J Am Geriatr Soc* 1992;40(3):203-7.  
8  
9 28. Newton RA. Validity of the multi-directional reach test: a practical measure for limits of  
10 stability in older adults. *J Gerontol A Biol Sci Med Sci* 2001;56(4):M248-52.  
11  
12 29. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al.  
13 The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive  
14 impairment. *J Am Geriatr Soc* 2005;53(4):695-9.  
15  
16 30. Ismail Z, Rajji TK, Shulman KI. Brief cognitive screening instruments: an update. *Int J*  
17 *Geriatr Psychiatry* 2010;25(2):111-20.  
18  
19 31. Holden MK, Gill KM, Magliozzi MR, Nathan J, Piehl-Baker L. Clinical gait assessment  
20 in the neurologically impaired. Reliability and meaningfulness. *Phys Ther*  
21 1984;64(1):35-40.  
22  
23 32. EuroQol-Group. EuroQol--a new facility for the measurement of health-related quality of  
24 life. *Health Policy* 1990;16(3):199-208.  
25  
26 33. Wood-Dauphinee SL, Opzoomer MA, Williams JI, Marchand B, Spitzer WO. Assessment  
27 of global function: The Reintegration to Normal Living Index. *Arch Phys Med Rehabil*  
28 1988;69(8):583-90.  
29  
30 34. Wood-Dauphinee S, Williams JI. Reintegration to Normal Living as a proxy to quality of  
31 life. *J Chronic Dis* 1987;40(6):491-502.  
32  
33 35. Salisbury LG, Merriweather JL, Walsh TS. Rehabilitation after critical illness: could a  
34 ward-based generic rehabilitation assistant promote recovery? *Nurs Crit Care*  
35 2010;15(2):57-65.  
36  
37 36. van den Berg-Emons RJ, L'Ortye AA, Buffart LM, Nieuwenhuijsen C, Nooijen CF,  
38 Bergen MP, et al. Validation of the Physical Activity Scale for individuals with  
39 physical disabilities. *Arch Phys Med Rehabil* 2011;92(6):923-8.  
40  
41 37. Armitage P, Colton T. *Encyclopedia of Biostatistics*. Chichester: Wiley, 1998.  
42  
43 38. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. *Journal of*  
44 *the American Statistical Association* 1958;53(282):457-481.  
45  
46 39. Kleinbaum D, Klein M. *Survival Analysis. A Self-Learning Text*. 3rd ed. New York:  
47 Springer, 2012.  
48  
49 40. Hosmer D, Lemeshow S, May S. *Applied Survival Analysis: Regression Modeling of Time*  
50 *to Event Data*. 2nd ed. New York: John Wiley & Sons, Inc., 2008.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



- 1  
2  
3 41. Spiegelhalter DJ. Probabilistic prediction in patient management and clinical trials. *Stat*  
4 *Med* 1986;5(5):421-33.  
5  
6 42. Steyerberg EW, Eijkemans MJ, Harrell FE, Jr., Habbema JD. Prognostic modelling with  
7 logistic regression analysis: a comparison of selection and estimation methods in small  
8 data sets. *Stat Med* 2000;19(8):1059-79.  
9  
10 43. Hosmer DW, Lemeshow S. *Applied Logistic Regression*. 2ed ed. New York: John Wiley  
11 & Sons, Inc., 2000.  
12  
13 44. Schweickert WD, Pohlman MC, Pohlman AS, Nigos C, Pawlik AJ, Esbrook CL, et al.  
14 Early physical and occupational therapy in mechanically ventilated, critically ill  
15 patients: a randomised controlled trial. *Lancet*, 2009:1874-82.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1** Summary of outcome measures and time points of assessment in GymNAST

	Baseline	Daily	Biweekly (T1 to T12)	Follow-up (FU 1 and 2)
<b>Amount and content of Physical Rehabilitation</b>				
Physiotherapy		x		x
Occupational Therapy		x		x
Other therapies (e.g. groups)		x		x
<b>Primary Outcome</b>				
FAC and STS	x	x		
<b>Delir measures</b>				
RASS	x		x	
<b>Strength measures</b>				
MRC score	x		x	x
Grip strength	x		x	x
<b>Physical function measures</b>				
PFIT and PFIT-S	x		x	x
FSS-ICU score	x		x	x
10m walking time	x		x	x
6-MWT	x		x	x
Pain (VAS)	x		x	x
functional reach	x		x	x
<b>Cognition measures</b>				
MOCA	x		x	x
CDT	x		x	x
<b>Activities and Mobility</b>				
BI	x		x	x
PASIPD				x
<b>Participation and quality of life</b>				
EQ-5D				x
RNL-Index				x

# BMJ Open

## The General Weakness Syndrome Therapy (GymNAST) study: protocol for a cohort study on recovery on walking function.

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-006168.R1
Article Type:	Protocol
Date Submitted by the Author:	26-Aug-2014
Complete List of Authors:	Mehrholz, Jan; Technische Universität Dresden, Department of Public Health, Medizinische Fakultät ‚Carl Gustav Carus‘ Mückel, Simone; Private Europäische Medizinische Akademie der Klinik Bavaria in Kreischa, Wissenschaftliches Institut Oehmichen, Frank; Klinik Bavaria Kreischa, Fach und Privatkrankenhaus Pohl, Marcus; Klinik Bavaria Kreischa, Fach und Privatkrankenhaus
<b>Primary Subject Heading</b>:	Intensive care
Secondary Subject Heading:	Evidence based practice, Rehabilitation medicine
Keywords:	Adult intensive & critical care < ANAESTHETICS, REHABILITATION MEDICINE, Adult neurology < NEUROLOGY

SCHOLARONE™  
Manuscripts

1  
2  
3 **The General Weakness Syndrome Therapy (GymNAST) study: protocol for a cohort**  
4 **study on recovery on walking function.**  
5

6  
7 Jan Mehrholz<sup>1,3\*</sup>, Simone Mückel<sup>1</sup>, Frank Oehmichen<sup>2</sup> and Marcus Pohl<sup>2</sup>  
8

9  
10 <sup>1</sup> *Wissenschaftliches Institut, Private Europäische Medizinische Akademie der Klinik Bavaria*  
11 *in Kreischa, An der Wolfsschlucht 1-2, 01731 Kreischa, Germany*  
12

13  
14 <sup>2</sup> *Fach und Privatkrankenhaus, Klinik Bavaria in Kreischa, An der Wolfsschlucht 1-2, 01731*  
15 *Kreischa, Germany*  
16

17  
18 <sup>3</sup> *Department of Public Health, Medizinische Fakultät, Carl Gustav Carus, Technische*  
19 *Universität Dresden, Germany*  
20

21  
22 **\*Corresponding author**  
23

24 Prof. Dr. Jan Mehrholz, Wissenschaftliches Institut, Private Europäische Medizinische  
25 Akademie der Klinik Bavaria in Kreischa GmbH, An der Wolfsschlucht 1-2, 01731 Kreischa,  
26 Germany  
27  
28

29  
30 Tel: ++49 35206 62054  
31

32  
33 Fax: ++49 35206 63517  
34

35 [jan.mehrholz@klinik-bavaria.de](mailto:jan.mehrholz@klinik-bavaria.de)  
36  
37

38  
39  
40 Short title: Study protocol: General Weakness Syndrome Therapy  
41

42  
43 Keywords: intensive care - rehabilitation - walking - muscle weakness  
44

45  
46 Word count: 4 698  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

Introduction: Critical illness myopathy (CIM) and polyneuropathy (CIP) are common complications of critical illness that frequently occur together. Both cause so called intensive-care-unit-acquired (ICU)-acquired muscle weakness. This weakness of limb muscles increases morbidity and delay rehabilitation and recovery of walking ability. Although full recovery has been reported people with severe weakness may take months to improve walking. Focused physical rehabilitation of people with ICU-acquired muscle weakness is therefore of great importance.

However, although physical rehabilitation is common, detailed knowledge about the pattern and the time course of recovery of walking function are not well understood.

Therefore the aim of the General Weakness Syndrome Therapy (GymNAST) study is to describe the time course of recovery of walking function and other activities of daily living in these patients.

Methods and analysis: We conduct a prospective cohort study of people with ICU-acquired muscle weakness with defined diagnosis of CIM or CIP.

Based on our sample size calculation, approximately 150 patients will be recruited from the intensive care unit of our hospital in Germany. Amount and content of physical rehabilitation, clinical tests e.g. muscle strength and motor function and neuropsychological assessments will be used as independent variables. The primary outcomes will include recovery of walking function and mobility. Secondary outcomes will include global motor function, activities in daily life and participation.

Ethics and dissemination: The study is being carried out in agreement with the Declaration of Helsinki and conducted with the approval of the local medical Ethics Committee (Landesärztekammer Sachsen, Germany, reference number EK-BR-32/13-1) and with the understanding and written consent of each patient's guardian.

The results of this study will be published in peer-reviewed journals and disseminated to the medical society and general public.

## Article Summary

### Article focus:

The aim of the General Weakness Syndrome Therapy (GymNAST) study is to determine the time course of recovery of walking function, to describe the detailed content of physical rehabilitation and also to describe possible risk factors and chances for recovery of walking function in the first year after ICU-acquired muscle weakness.

### Key messages:

This study will determine how people with ICU-acquired muscle weakness are related to clinical characteristics and describe the time course of motor and cognitive performance and activities of daily life.

The results will be of interest of clinicians working with critical ill patients and will give insights into the black box of rehabilitation and its impact on recovery of ICU-acquired muscle weakness due to CIM/CIP. The results of this study may therefore inform patients and their caregivers, therapists working in rehabilitation to choose the most appropriate treatment, and to develop adapted rehab programs.

### Strengths and limitations:

The strength of this study is that it is one of the first prospective cohort studies in the first year of ICU-acquired muscle weakness with daily documentation of physical rehabilitation and walking function. Multiple repeated assessments, with a wide range of clinical measures will be done. Such a measurement design has several advantages compared to other prognostic studies done so far using just two measurements in time. Our longitudinal repeated measure design may provide further insights into dynamics of recovery of walking function and other activities over the first year of people with ICU-acquired muscle weakness.

One limitation could be that most severe affected patients have to be excluded in this study. This may reduce the generalisability of the results to the whole population critical ill patients. Another limitation might be that no objective measures for muscle weakness such as electromyography or magnetic resonance tomography will be used.

## Introduction

Critical illness myopathy (CIM) and polyneuropathy (CIP) are common complications of critical illness that frequently occur together. Both cause so called intensive-care-unit-acquired (ICU)-acquired muscle weakness. According to Norton-Craft this weakness is characterized by a profound weakness that is greater than might be expected to result from prolonged bed rest [1]. The weakness of limb muscles limits significantly activities and assistance for basic activities such as sit-to stand or sitting and standing is oftentimes required [2-4]. This increases morbidity and delays rehabilitation and recovery of walking [5 6]. Although full recovery has been reported in approximately 50% of people with ICU-acquired muscle weakness, improvement is related to the severity of the condition e.g. people with severe weakness may take months to improve, or even remain severely affected [7 8]. Focused physical rehabilitation of people with ICU-acquired muscle weakness is therefore of great importance. There is practical evidence that physical rehabilitation of patients can be implemented with few adverse effects [1]. In recent years appropriate assessments were developed and description of suitable physical intervention strategies were described in the literature [1 8-12].

However, detailed knowledge about the time course of recovery of walking and other activities, their risk factors and chances for good recovery such are not well described or understood. Furthermore it lacks on detailed description of physical rehabilitation and on a repeated measure cohort study in the first year of people with ICU-acquired muscle weakness. Such a design would give better insights in to the time course of recovery of walking function and activities of these patients.

Therefore the aim of the General Weakness Syndrome Therapy (GymNAST) study is to describe and to identify time course and the pattern of recovery of walking, motor functions and of activities of daily living in these patients. Other aims are to describe the detailed content of physical rehabilitation and to develop a multivariate model of risk factors for recovery of walking function in the first year of ICU-acquired muscle weakness.

Here we describe the design and protocol of the GymNAST study, which is an appropriate large prospective cohort study of critical ill people with ICU-acquired muscle weakness including a detailed description of physical rehabilitation contents. This study will help to understand the time course and pattern of recovery of walking function and of activities of

1  
2  
3 daily live. Furthermore a multivariate model for recovery of walking ability will be  
4 developed.  
5

## 6 7 **Methods and analysis**

### 8 9 Study objectives

10  
11 The primary objective of the GymNAST study is to assess the time course of regaining  
12 walking and sit to stand ability as important activities of daily live  
13

14  
15 Secondary objectives are to:

- 16  
17 • describe the concomitant physical rehabilitation therapies
- 18  
19 • describe the clinical course of recovery using standardized outcome measures and their  
20  
21 results
- 22  
23 • identify a prognostic model for regain walking and sit to stand abilities  
24  
25  
26  
27

### 28 29 30 Design

31  
32 We conduct a prospective cohort study of people with ICU-acquired muscle weakness and  
33 defined diagnosis of CIM/CIP. We started in 2013 and the final assessments including follow  
34 up will be made in 2015.  
35  
36

37  
38 Based on our sample size calculation [13 14], approximately 150 patients will be recruited  
39 from a intensive care unit of our hospital in Germany [15] over the time course of three years.  
40 In a first cross sectional pilot study in our hospital we found a point prevalence of 88 patients  
41 with defined diagnosis of CIM/CIP and ICU-acquired muscle weakness per month [16].  
42 Therefore, based on this pilot study it seems to be realistically to reach the anticipated sample  
43 size in our cohort study within three years of recruitment.  
44  
45  
46  
47

### 48 49 Study population

50  
51 Patients with ICU-acquired muscle weakness and defined diagnosis of CIM/CIP will be  
52 recruited consecutively from the intensive care units of our acute care, weaning and early  
53 rehabilitation centers of Klinik Bavaria Kreischa in Germany.  
54  
55

### 56 57 Inclusion criteria



- patient is chronic critical ill defined as more than 21 days intensive care unit treatment including mechanical ventilation (we will include patients after 3 weeks of intensive care unit treatment including mechanical ventilation. Many patients will still be treated and monitored at this time point on our ICU).
- defined diagnosis of Critical illness myopathy (CIM) and polyneuropathy (CIP) [17 18] (we will involve a neurologist consultant for the defined diagnosis of CIM/CIP and we will use neurophysiological techniques and also the clinical criteria for the diagnosis of CIM and/or CIP [17 18] and differential diagnosis. However we will not apply muscle biopsy for differential diagnosis)
- muscle weakness defined as a Medical Research Council (MRC) sum score of less than 48 points [1]
- more than 18 years old
- Richmond Agitation Sedation Scale (RASS) score from -1 to 2 [19]
- written informed consent of the patient or his legal guardian

#### Exclusion criteria

- Patients receiving palliative care
- Co-morbidities of the trunk or the lower limbs interfering with upright posture and walking function (e.g. Amputation or fracture of lower limb)
- Other neuromuscular or neurological disease and/or syndromes causing weakness in patients in the ICU (we will exclude patients with diseases and syndromes causing weakness in patients in the ICU[8], due to Guillain–Barré syndrome, myasthenia gravis, porphyria, Eaton–Lambert syndrome, amyotrophic lateral sclerosis, vasculitic neuropathy, cervical myelopathy and botulism)
- severe physical co-morbidity before becoming critical ill (e.g, frailty due to neurological conditions)

#### Procedure

Eligible patients will be screened and afterwards will get oral and written information about the study from their treating physician or researcher. After written informed consent the

1  
2  
3 demographic and clinical characteristics will be measured (baseline assessment T0). Patients  
4 will then be measured every two weeks after baseline up to 20 weeks (week two (T1), week  
5 four (T2), week six (T3), week eight (T4) week ten (T5) and so on until week twenty (T10)).  
6  
7 Two follow ups are planned: FU1 after six month and FU2 after one year after study entry.  
8  
9 For follow-up assessments (FU1 and FU2), patients and their guardians will be informed and  
10 invited by letter and telephone to participate.  
11

12  
13 The amount and the content of physical rehabilitation, activities of daily life such as the  
14 ability to walk will be documented every day by physiotherapists and occupational therapist  
15 using predefined sheets [16]. All assessments and standardized measures will be administered  
16 by trained and experienced assessors or therapists in the hospital and/or inpatient  
17 rehabilitation, at home or residence facility. Additionally, we will try to get all information  
18 about the content and duration of physiotherapy and or physical rehabilitation applied at all  
19 stages of illness.  
20  
21  
22  
23  
24  
25  
26  
27

### 28 Measures and Outcomes

29  
30  
31 Primary outcomes of the GYMNAST study are walking ability and ability to stand up alone.  
32

33 To measure walking ability the Functional Ambulation Categories (FAC) is used [20]. The  
34 ability to stand up alone will be measured by the ability to stand up from a chair  
35 independently, STS (standardised chair height is defined with 120% of knee height).  
36  
37  
38

39 Secondary outcomes includes  
40

- 41 • Richmond Agitation-Sedation Scale (RASS) [19]
- 42
- 43 • activities measured with the Barthel Index (BI; 10 items) [21]
- 44
- 45 • muscle strength of the upper (shoulder, elbow and wrist) and lower limb (hip, knee  
46 and ankle) using the Medical Research Council (MRC) [1 22]
- 47
- 48 • grip strength (measured bilaterally using a dynamometer) [23 24]
- 49
- 50 • Functional Status Score for the Intensive Care Unit Scored (FSS-ICU) [25]
- 51
- 52 • Physical Function –ICU Test (PFIT) [26] and Physical Function –ICU Test- Scored  
53 (PFIT-S) [27]
- 54  
55  
56  
57  
58  
59  
60

- Pain using a visual analogue scale
- Lateral and frontal sit and stance balance (functional reach) [28 29]
- cognitive measures (Montreal Cognitive Assessment (MoCA) [30] and clock drawing test (CDT) [31])
- walking ability (0- 5; FAC) [32], walking speed (we will use a 10m walking test, adopting a 14-m course and will measure the walking speed over the central 10 m) and walking endurance (we will use a six minute walking test, using 40m course and will measure the distance walked in six minutes; if patients cannot walk the whole six minutes we will measure the maximum walking distance here) [5 6]
- quality of life (EQ-5D) [33]
- participation (Reintegration to Normal Living, RNL-Index) [34 35]
- fitness and mobility (PASIPD) [36 37]

All measures chosen are frequently used in research and/or daily clinical practice dealing with the above described patients.

The primary outcome variables FAC and STS will be measured daily with standardized sheets for this purpose.

At baseline assessment (T0) and then every two weeks until twenty weeks after baseline (T10) we will assess RASS, BI, muscle strength of the upper and lower limb (MRC), grip strength, FSS-ICU, PFIT and PFIT-S, pain, functional reach, cognitive measures, walking speed and endurance.

At follow ups FU1 after six month and FU2 after one year after study entry we will measure the EQ-5D, the RNL-Index and PASIPD. Additionally we will be gathering detailed survival data.

Tables 1 gives a detailed overview of the variables used at each time point of study.

#### Possible clinical prognostic factors

1  
2  
3 Depending on the primary outcomes (walking ability and activities), a range of potentially  
4 prognostic factors will be taken into account. These factors include: demographic variables  
5 (such as age, sex), clinical variables (such as FSS-ICU, PFIT-S) and medical characteristics  
6 (such as diagnoses, reason for ICU-treatment, duration of mechanical ventilation, duration of  
7 illness) and anthropometric measures, such as body weight and body mass index (but not limb  
8 circumference).  
9  
10  
11  
12

### 13 14 15 16 Planned statistical analyses

17  
18 We will use descriptive analyses, e.g. means and standard deviations of the continuous  
19 variables and frequencies and proportions of categorical variables as appropriate [38]. We will  
20 explain differences across the time points (T1–T10 and FU1 - FU2) descriptively and with  
21 appropriate inference statistics use parametric and non-parametric tests as appropriate e.g.  
22 repeated measures analysis of variance [38]. The global alpha level will be set at 0.05.  
23  
24  
25  
26  
27

28 Time to regain walking ability and time to stand up from a chair independently will be the  
29 main end point for this analysis. The following factors will be analyzed for their association  
30 with these endpoints:  
31  
32

- 33 • demographic variables (such as age and sex),
  - 34 • clinical variables (such as muscle strength, FSS-ICU, PFIT-S) and
  - 35 • medical characteristics (such as diagnosis and duration of illness)
- 36  
37  
38  
39  
40

41 The probability in regaining walking ability and sit to stand ability will be calculated with the  
42 method of Kaplan and Meier [39]. Cox regression analysis will be used to estimate relative  
43 hazard rates and to test for differences in variables or trends in subgroups of each factor [40].  
44 A stepwise multivariable Cox regression analysis will be applied with a variable selection [40  
45 41].  
46  
47  
48  
49

50 Time to event or censoring will be defined as time difference between study entry (T0) and  
51 date of reaching a FAC score equal to 3, or the possible censoring dates of discharge or dead,  
52 respectively. Possible prognostic factors from demographic, clinical and medical variables  
53 will be selected for a multivariable model based on clinical and statistical significance [42-  
54 44]. The final model selection will be performed based on clinical decision, together with  
55 Akaike's information criterion (AIC) and the Bayesian information criterion (BIC) [41]. Aim  
56  
57  
58  
59  
60

1  
2  
3 of our analysis is to *explain* the dependent variable (regaining walking function) by a  
4 multivariate Cox proportional hazard model with not too many variables.  
5  
6

7 To prevent overfitting, only variables with clinically important *and* statistically significant  
8 bivariate association with our endpoint will be included in the final model [41].  
9

10 The effects of prognostic factors in the final model will be expressed as hazard ratios (HR)  
11 with 95% confidence intervals (CI) after a graphical assessment of proportionality of hazards.  
12  
13

14 We will use SAS/STAT 9.3 for all statistical procedures (SAS Institute Inc., Cary, NC, USA).  
15 The proportional hazards assumption will be tested with the implemented function (proc  
16 phreg).  
17  
18  
19  
20  
21  
22

## 23 Results

24 We will describe the demographic and clinical characteristics at each of the individual time  
25 points (T1–T10 and FU1 - FU2) descriptively. We will describe the probability in regaining  
26 walking ability and other activities with the method of Kaplan and Meier. We will present the  
27 final statistical multivariate model for regaining walking ability.  
28  
29  
30  
31  
32

## 33 Sample size and power calculation

34 The sample size needed in the GymNAST study is calculated using the method for one of the  
35 most cited recommendation for prognostic research: the ‘rule of ten events per variable  
36 (EPV)’ [13 14 44]. Based on our sample size calculation using the EPV-approach  
37 approximately 150 patients will be recruited from the intensive care unit of our long term  
38 intensive care hospital in Germany [15]. We anticipate reaching this study size over the time  
39 course of three years. Our confidence results from a cross-sectional study. We found a point  
40 prevalence of 88 patients per month of people with ICU-acquired muscle weakness and  
41 defined diagnosis of CIM/CIP in our intensive care units [16]. Therefore, based on this pilot  
42 study it seems to be a realistically to reach the estimated sample size in our cohort study  
43 within three years of recruitment.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54

## 55 **Ethics and Dissemination**

### 56 Ethical considerations

57  
58  
59  
60

1  
2  
3 The GymNAST study will be conducted in accordance with the 'Helsinki Declaration'. The  
4 study is non-invasive, imposes no risk on patients, seems to have enough power to detect  
5 meaningful determinants and our protocol has been approved by the medical ethical  
6 committees. Furthermore, written informed consent is obtained from all participants or if  
7 necessary from its legal guardian. The study will be registered before publication.  
8  
9

### 10 11 Dissemination

12  
13  
14 The results obtained will be disseminated to the scientific, medical and general public by  
15 publication in national and international peer-reviewed journals, as well as by presentations in  
16 conferences and meetings with clinicians dealing with patients with ICU-acquired muscle  
17 weakness syndrome.  
18  
19  
20  
21

### 22 23 **Discussion**

24  
25  
26 The GymNAST study will be one of the first studies with rigorous repeated measures over the  
27 time course of one year with daily documentation of rehabilitation therapies of people with  
28 ICU-acquired muscle weakness. Also a wide range of functional variables to describe the  
29 pattern of regaining of walking is used.  
30  
31  
32  
33

34  
35 Until now many prognostic studies including people with ICU-acquired muscle weakness  
36 used rather a traditional prognostic design using a baseline test and compared with ICU  
37 discharge and follow-ups [5 26 27] and only some studies measures continuously over time  
38 [45]. However, instead of comparing two or more measurements of the patient's performance  
39 it seems to be more informative to analyze the dynamic recovery systematically using equal  
40 time intervals over an appropriate time period e.g. with daily assessments of walking function  
41 and with daily description of physical rehabilitation over months. This might provide a more  
42 detailed understanding of the pattern and the dynamics of recovery of walking function, and  
43 allows a better understanding of changes in clinical characteristics and the applied  
44 rehabilitation therapies.  
45  
46  
47  
48  
49  
50

51  
52 Also, detailed knowledge about the time course of recovery of walking ability, their risks and  
53 chances (e.g. clinical and therapeutic determinants) are still not very well understood. The  
54 present study documents clinical determinants at equal time intervals (every two weeks) and  
55 will document therapeutic determinants daily.  
56  
57  
58  
59  
60

1  
2  
3 Strong aspects of GymNAST are therefore its prospective design with multiple repeated  
4 assessments during the first year after illness using equal time intervals of people with ICU-  
5 acquired muscle weakness. The present study might therefore provide new and more detailed  
6 information about the pattern of walking recovery and the physical rehabilitation content of  
7 people with ICU-acquired muscle weakness.  
8  
9  
10

11  
12 A potential limitation of the study is that the most seriously affected patients might be unable  
13 to participate, thereby reducing the possibility to generalize the results to the whole critical ill  
14 population. Another limitation might be that no objective measures for muscle weakness such  
15 as electromyography or magnetic resonance tomography will be used.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Authors' contributions:**

J.M., S.M, FO and M.P. planned the study. F.O. and M.P. contributed to the procurement of funding. J.M., S.M, and M.P. developed the protocol. All authors contributed to and checked the final draft of the manuscript.

**Funding statement:**

This study is financially supported by the Centre of Research from Klinik Bavaria, Kreischa, Germany and by the Department of Public Health, Medizinische Fakultät ,Carl Gustav Carus', Technische Universität Dresden, Germany

**Competing interests statement:**

None declared



## Literatur

1. Nordon-Craft A, Moss M, Quan D, et al. Intensive Care Unit-Acquired Weakness. *Phys Ther* 2012;92(12):1494-506.
2. Fan E. Critical illness neuromyopathy and the role of physical therapy and rehabilitation in critically ill patients. *Respir Care* 2012;57(6):933-44; discussion 944-6.
3. Herridge MS. The challenge of designing a post-critical illness rehabilitation intervention. *Crit Care* 2011;15(5):1002.
4. Ohtake PJ, Strasser DC, Needham DM. Rehabilitation for people with critical illness: taking the next steps. *Physical Therapy* 2012;92(12):1484-8.
5. Herridge MS, Cheung AM, Tansey CM, et al. One-year outcomes in survivors of the acute respiratory distress syndrome. *N Engl J Med* 2003;348(8):683-93.
6. Herridge MS, Tansey CM, Matte A, et al. Functional disability 5 years after acute respiratory distress syndrome. *N Engl J Med* 2011;364(14):1293-304.
7. Hermans G, De Jonghe B, Bruyninckx F, et al. Clinical review: critical illness polyneuropathy and myopathy. *Critical Care*, 2008:238.
8. Kress J, Hall J. ICU-acquired weakness and recovery from critical illness. *N Engl J Med* 2014;370(17):1626-35.
9. Denehy L, Berney S, Skinner E, Edbrook L, et al. Evaluation of Exercise Rehabilitation for Survivors of Intensive Care: Protocol for Single Blind Randomised Controlled Trial. *The Open Critical Care Medicine Journal* 2008;1:39-47.
10. Denehy L, Berney S, Skinner E, et al. Evaluation of exercise rehabilitation for survivors of intensive care: protocol for single blind randomised controlled trial. *Open Critical Care Medicine Journal*, 2008:39-47.
11. Denehy L, Skinner EH, Edbrooke L, et al. Exercise rehabilitation for patients with critical illness: a randomized controlled trial with 12 months follow up. *Crit Care* 2013;17(4):R156.
12. Nordon-Craft A, Schenkman M, Ridgeway K, et al. Physical therapy management and patient outcomes following ICU-acquired weakness: a case series. *J Neurol Phys Ther* 2011;35(3):133-40.
13. Peduzzi P, Concato J, Feinstein AR, et al. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. *J Clin Epidemiol* 1995;48(12):1503-10.
14. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. *Am J Epidemiol* 2007;165(6):710-8.

15. Mallett S, Royston P, Dutton S, et al. Reporting methods in studies developing prognostic models in cancer: a review. *BMC Med* 2010;8:20.
16. Mückel S, Mehrholz K, Mehrholz J, et al. Treatment approaches of patients with ICU acquired weakness [Behandlungsansätze bei Patienten mit auf der Intensivstation erworbenen Schwächesyndrom]. *Neuroreha* 2013;5(1):40-43.
17. Latronico N, Rasulo FA. Presentation and management of ICU myopathy and neuropathy. *Curr Opin Crit Care* 2010;16(2):123-7.
18. Latronico N, Bolton C. Critical illness polyneuropathy and myopathy: a major cause of muscle weakness and paralysis. *Lancet Neurology* 2011;10(10):931-41.
19. Sessler CN, Gosnell MS, Grap MJ, et al. The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients. *Am J Respir Crit Care Med* 2002;166(10):1338-44.
20. Holden MK, Gill KM, Magliozzi MR. Gait assessment for neurologically impaired patients. Standards for outcome assessment. *Phys Ther* 1986;66(10):1530-9.
21. Mahoney FI, Barthel DW. Functional Evaluation: The Barthel Index. *Md State Med J* 1965;14:61-5.
22. Kleyweg RP, van der Meche FG, Schmitz PI. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barre syndrome. *Muscle Nerve* 1991;14(11):1103-9.
23. Mathiowetz V, Weber K, Volland G, et al. Reliability and validity of grip and pinch strength evaluations. *J Hand Surg Am* 1984;9(2):222-6.
24. Mathiowetz V, Kashman N, Volland G, et al. Grip and pinch strength: normative data for adults. *Arch Phys Med Rehabil* 1985;66(2):69-74.
25. Zanni JM, Korupolu R, Fan E, Pradhan P, et al. Rehabilitation therapy and outcomes in acute respiratory failure: an observational pilot project. *J Crit Care* 2010;25(2):254-62.
26. Nordon-Craft A, Schenkman M, Edbrooke L, et al. The Physical Function Intensive Care Test: Implementation in Survivors of Critical Illness. *Phys Ther* 2014.
27. Denehy L, de Morton N, Skinner E, et al. A Physical Function Test for Use in the Intensive Care Unit: Validity, Responsiveness, and Predictive Utility of the Physical Function in Intensive Care Test (Scored). *Phys Ther* 2013;93(12):1636-45.
28. Weiner DK, Duncan PW, Chandler J, et al. Functional reach: a marker of physical frailty. *J Am Geriatr Soc* 1992;40(3):203-7.

- 1  
2  
3 29. Newton RA. Validity of the multi-directional reach test: a practical measure for limits of  
4 stability in older adults. *J Gerontol A Biol Sci Med Sci* 2001;56(4):M248-52.  
5  
6 30. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment,  
7 MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc*  
8 2005;53(4):695-9.  
9  
10 31. Ismail Z, Rajji TK, Shulman KI. Brief cognitive screening instruments: an update. *Int J*  
11 *Geriatr Psychiatry* 2010;25(2):111-20.  
12  
13 32. Holden MK, Gill KM, Magliozzi MR, et al. Clinical gait assessment in the neurologically  
14 impaired. Reliability and meaningfulness. *Phys Ther* 1984;64(1):35-40.  
15  
16 33. EuroQol-Group. EuroQol--a new facility for the measurement of health-related quality of  
17 life. *Health Policy* 1990;16(3):199-208.  
18  
19 34. Wood-Dauphinee SL, Opzoomer MA, Williams JI, et al. Assessment of global function:  
20 The Reintegration to Normal Living Index. *Arch Phys Med Rehabil* 1988;69(8):583-  
21 90.  
22  
23 35. Wood-Dauphinee S, Williams JI. Reintegration to Normal Living as a proxy to quality of  
24 life. *J Chronic Dis* 1987;40(6):491-502.  
25  
26 36. Salisbury LG, Merriweather JL, Walsh TS. Rehabilitation after critical illness: could a  
27 ward-based generic rehabilitation assistant promote recovery? *Nurs Crit Care*  
28 2010;15(2):57-65.  
29  
30 37. van den Berg-Emons RJ, L'Ortye AA, et al. Validation of the Physical Activity Scale for  
31 individuals with physical disabilities. *Arch Phys Med Rehabil* 2011;92(6):923-8.  
32  
33 38. Armitage P, Colton T. *Encyclopedia of Biostatistics*. Chichester: Wiley, 1998.  
34  
35 39. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. *Journal of*  
36 *the American Statistical Association* 1958;53(282):457-481.  
37  
38 40. Kleinbaum D, Klein M. *Survival Analysis. A Self-Learning Text*. 3rd ed. New York:  
39 Springer, 2012.  
40  
41 41. Hosmer D, Lemeshow S, May S. *Applied Survival Analysis: Regression Modeling of Time*  
42 *to Event Data*. 2nd ed. New York: John Wiley & Sons, Inc., 2008.  
43  
44 42. Spiegelhalter DJ. Probabilistic prediction in patient management and clinical trials. *Stat*  
45 *Med* 1986;5(5):421-33.  
46  
47 43. Steyerberg EW, Eijkemans MJ, Harrell FE, Jr., et al. Prognostic modelling with logistic  
48 regression analysis: a comparison of selection and estimation methods in small data  
49 sets. *Stat Med* 2000;19(8):1059-79.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 44. Hosmer DW, Lemeshow S. *Applied Logistic Regression*. 2ed ed. New York: John Wiley  
4 & Sons, Inc., 2000.  
5  
6 45. Schweickert WD, Pohlman MC, Pohlman AS, et al. Early physical and occupational  
7 therapy in mechanically ventilated, critically ill patients: a randomised controlled trial.  
8 *Lancet*, 2009:1874-82.  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1** Summary of outcome measures and time points of assessment in GymNAST

	Baseline	Daily	Biweekly (T1 to T12)	Follow-up (FU 1 and 2)
<b>Amount and content of Physical Rehabilitation</b>				
Physiotherapy		x		x
Occupational Therapy		x		x
Other therapies (e.g. groups)		x		x
<b>Primary Outcome</b>				
FAC and STS	x	x		
<b>Delir measures</b>				
RASS	x		x	
<b>Strength measures</b>				
MRC score	x		x	x
Grip strength	x		x	x
<b>Physical function measures</b>				
PFIT and PFIT-S	x		x	x
FSS-ICU score	x		x	x
10m walking time	x		x	x
6-MWT	x		x	x
Pain (VAS)	x		x	x
functional reach	x		x	x
<b>Cognition measures</b>				
MOCA	x		x	x
CDT	x		x	x
<b>Activities and Mobility</b>				
BI	x		x	x
PASIPD				x
<b>Participation and quality of life</b>				
EQ-5D				x
RNL-Index				x

1  
2  
3 *Abbreviations:* GymNAST: General Weakness Syndrome Therapy study; FU= Follow Up; T=  
4 Time point; FAC: Functional Ambulation; STS: ability to stand up from a chair  
5 independently; RASS: Richmond Agitation-Sedation Scale; MRC: Medical Research Council  
6 (muscle strength of the upper (shoulder, elbow and wrist) and lower limb (hip, knee and  
7 ankle)); PFIT: Physical Function –Intensive Care Unit- Test; PFIT-S: Physical Function –  
8 Intensive Care Unit Test- Scored; FSS-ICU: Functional Status Score for the Intensive Care  
9 Unit Scored; 6-MWT: six minute walking test; VAS: visual analogue scale; MOCA=  
10 Montreal Cognitive Assessment; CDT: clock drawing test; BI: Barthel Index; PASIPD:  
11 Physical Activity Scale for Individuals with Physical Disabilities; EQ-5D: EuroQol (5  
12 dimensions); RNL-Index: Reintegration to Normal Living Index  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7 **The General Weakness Syndrome Therapy (GymNAST) study: protocol for a cohort**  
8 **study on recovery on walking function.**  
9

10 Jan Mehrholz<sup>1,3\*</sup>, Simone Mückel<sup>1</sup>, Frank Oehmichen<sup>2</sup> and Marcus Pohl<sup>2</sup>

11  
12 <sup>1</sup> *Wissenschaftliches Institut, Private Europäische Medizinische Akademie der Klinik Bavaria*  
13 *in Kreischa, An der Wolfsschlucht 1-2, 01731 Kreischa, Germany*

14  
15 <sup>2</sup> *Fach und Privatkrankenhaus, Klinik Bavaria in Kreischa, An der Wolfsschlucht 1-2, 01731*  
16 *Kreischa, Germany*

17  
18 <sup>3</sup> *Department of Public Health, Medizinische Fakultät, Carl Gustav Carus, Technische*  
19 *Universität Dresden, Germany*

20  
21  
22  
23 **\*Corresponding author**

24  
25 Prof. Dr. Jan Mehrholz, Wissenschaftliches Institut, Private Europäische Medizinische  
26 Akademie der Klinik Bavaria in Kreischa GmbH, An der Wolfsschlucht 1-2, 01731 Kreischa,  
27 Germany  
28

29  
30 Tel: ++49 35206 62054

31  
32 Fax: ++49 35206 63517

33  
34 [jan.mehrholz@klinik-bavaria.de](mailto:jan.mehrholz@klinik-bavaria.de)  
35  
36  
37

38  
39 Short title: Study protocol: General Weakness Syndrome Therapy

40  
41 Keywords: intensive care - rehabilitation - walking - muscle weakness  
42

43 **Word count: 4 698**

Formatted: Font: Bold

## Abstract

Introduction: Critical illness myopathy (CIM) and polyneuropathy (CIP) are common complications of critical illness that frequently occur together. Both cause so called intensive-care-unit-acquired (ICU)-acquired muscle weakness. This weakness of limb muscles increases morbidity and delay rehabilitation and recovery of walking ability. Although full recovery has been reported people with severe weakness may take months to improve walking. Focused physical rehabilitation of people with ICU-acquired muscle weakness is therefore of great importance.

However, although physical rehabilitation is common, detailed knowledge about the pattern and the time course of recovery of walking function are not well understood.

Therefore the aim of the General Weakness Syndrome Therapy (GymNAST) study is to describe the time course of recovery of walking function and other activities of daily living in these patients.

Methods and analysis: We conduct a prospective cohort study of people with ICU-acquired muscle weakness with defined diagnosis of CIM or CIP.

Based on our sample size calculation, approximately 150 patients will be recruited from the intensive care unit of our hospital in Germany. Amount and content of physical rehabilitation, clinical tests e.g. muscle strength and motor function and neuropsychological assessments will be used as independent variables. The primary outcomes will include recovery of walking function and mobility. Secondary outcomes will include global motor function, activities in daily life and participation.

Ethics and dissemination: The study is being carried out in agreement with the Declaration of Helsinki and conducted with the approval of the local medical Ethics Committee (Landesärztekammer Sachsen, Germany, reference number EK-BR-32/13-1) and with the understanding and written consent of each patient's guardian.

The results of this study will be published in peer-reviewed journals and disseminated to the medical society and general public.



## Article Summary

### Article focus:

The aim of the General Weakness Syndrome Therapy (GymNAST) study is to determine the time course of recovery of walking function, to describe the detailed content of physical rehabilitation and also to describe possible risk factors and chances for recovery of walking function in the first year after ICU-acquired muscle weakness.

### Key messages:

This study will determine how people with ICU-acquired muscle weakness are related to clinical characteristics and describe the time course of motor and cognitive performance and activities of daily life.

The results will be of interest of clinicians working with critical ill patients and will give insights into the black box of rehabilitation and its impact on recovery of ICU-acquired muscle weakness due to CIM/CIP. The results of this study may therefore inform patients and their caregivers, therapists working in rehabilitation to choose the most appropriate treatment, and to develop adapted rehab programs.

### Strengths and limitations:

The strength of this study is that it is one of the first prospective cohort studies in the first year of ICU-acquired muscle weakness with daily documentation of physical rehabilitation and walking function. Multiple repeated assessments, with a wide range of clinical measures will be done. Such a measurement design has several advantages compared to other prognostic studies done so far using just two measurements in time. Our longitudinal repeated measure design may provide further insights into dynamics of recovery of walking function and other activities over the first year of people with ICU-acquired muscle weakness.

One limitation could be that most severe affected patients have to be excluded in this study. This may reduce the generalisability of the results to the whole population critical ill patients. Another limitation might be that no objective measures for muscle weakness such as electromyography or magnetic resonance tomography will be used.

## Introduction

Critical illness myopathy (CIM) and polyneuropathy (CIP) are common complications of critical illness that frequently occur together. Both cause so called intensive-care-unit-acquired (ICU)-acquired muscle weakness. According to Norton-Craft this weakness is characterized by a profound weakness that is greater than might be expected to result from prolonged bed rest [1]. The weakness of limb muscles limits significantly activities and assistance for basic activities such as sit-to stand or sitting and standing is oftentimes required [2-4]. This increases morbidity and delays rehabilitation and recovery of walking [5 6]. Although full recovery has been reported in approximately 50% of people with ICU-acquired muscle weakness, improvement is related to the severity of the condition e.g. people with severe weakness may take months to improve, or even remain severely affected [7 8]. Focused physical rehabilitation of people with ICU-acquired muscle weakness is therefore of great importance. There is practical evidence that physical rehabilitation of patients can be implemented with few adverse effects [1]. In recent years appropriate assessments were developed and description of suitable physical intervention strategies were described in the literature [1 8-12].

However, detailed knowledge about the time course of recovery of walking and other activities, their risk factors and chances for good recovery such are not well described or understood. Furthermore it lacks on detailed description of physical rehabilitation and on a repeated measure cohort study in the first year of people with ICU-acquired muscle weakness. Such a design would give better insights in to the time course of recovery of walking function and activities of these patients.

Therefore the aim of the General Weakness Syndrome Therapy (GymNAST) study is to describe and to identify time course and the pattern of recovery of walking, motor functions and of activities of daily living in these patients. Other aims are to describe the detailed content of physical rehabilitation and to develop a multivariate model of risk factors for recovery of walking function in the first year of ICU-acquired muscle weakness.

Here we describe the design and protocol of the GymNAST study, which is an appropriate large prospective cohort study of critical ill people with ICU-acquired muscle weakness including a detailed description of physical rehabilitation contents. This study will help to understand the time course and pattern of recovery of walking function and of activities of

1  
2  
3  
4  
5  
6  
7 daily live. Furthermore a multivariate model for recovery of walking ability will be  
8 developed.  
9

## 10 **Methods and analysis**

### 11 Study objectives

12  
13  
14 The primary objective of the GymNAST study is to assess the time course of regaining  
15 walking and sit to stand ability as important activities of daily live  
16

17 Secondary objectives are to:  
18

- 19 • describe the concomitant physical rehabilitation therapies
- 20
- 21 • describe the clinical course of recovery using standardized outcome measures and their
- 22 results
- 23
- 24 • identify a prognostic model for regain walking and sit to stand abilities
- 25
- 26
- 27
- 28
- 29

### 30 Design

31  
32 We conduct a prospective cohort study of people with ICU-acquired muscle weakness and  
33 defined diagnosis of CIM/CIP. We started in 2013 and the final assessments including follow  
34 up will be made in 2015.  
35  
36

37 Based on our sample size calculation [13 14], approximately 150 patients will be recruited  
38 from a intensive care unit of our hospital in Germany [15] over the time course of three years.  
39 In a first cross sectional pilot study in our hospital we found a point prevalence of 88 patients  
40 with defined diagnosis of CIM/CIP and ICU-acquired muscle weakness per month [16].  
41 Therefore, based on this pilot study it seems to be realistically to reach the anticipated sample  
42 size in our cohort study within three years of recruitment.  
43  
44  
45

### 46 Study population

47  
48 Patients with ICU-acquired muscle weakness and defined diagnosis of CIM/CIP will be  
49 recruited consecutively from the intensive care units of our acute care, weaning and early  
50 rehabilitation centers of Klinik Bavaria Kreischa in Germany.  
51  
52

### 53 Inclusion criteria

- patient is chronic critical ill **defined as more than 21 days intensive care unit treatment including mechanical ventilation (we will include patients after 3 weeks of intensive care unit treatment including mechanical ventilation. Many patients will still be treated and monitored at this time point on our ICU).**
- defined diagnosis of Critical illness myopathy (CIM) and polyneuropathy (CIP) [17 18] **(we will involve a neurologist consultant for the defined diagnosis of CIM/CIP and we will use neurophysiological techniques and also the clinical criteria for the diagnosis of CIM and/or CIP [17 18] and differential diagnosis. However we will not apply muscle biopsy for differential diagnosis)**
- muscle weakness defined as a Medical Research Council (MRC) sum score of less than 48 points [1]
- more than 18 years old
- Richmond Agitation Sedation Scale (RASS) score from -1 to 2 [19]
- written informed consent of the patient or his legal guardian

#### Exclusion criteria

- Patients receiving palliative care
- Co-morbidities of the trunk or the lower limbs interfering with upright posture and walking function (e.g. Amputation or fracture of lower limb)
- Other neuromuscular or neurological disease **and/or syndromes causing weakness in patients in the ICU (we will exclude patients with diseases and syndromes causing weakness in patients in the ICU[8], due to Guillain–Barré syndrome, myasthenia gravis, porphyria, Eaton–Lambert syndrome, amyotrophic lateral sclerosis, vasculitic neuropathy, cervical myelopathy and botulism)**
- severe physical co-morbidity before becoming critical ill (e.g. frailty due to neurological conditions)

#### Procedure

Eligible patients will be screened and afterwards will get oral and written information about the study from their treating physician or researcher. After written informed consent the

Formatted: Font: Bold

Formatted: Font: Bold

Formatted: Font: Bold

Formatted: Font: Bold

Formatted: Font: Bold

Formatted: Font: Bold

Formatted: Font: Bold

1  
2  
3  
4  
5  
6  
7 demographic and clinical characteristics will be measured (baseline assessment T0). Patients  
8 will then be measured every two weeks after baseline up to 20 weeks (week two (T1), week  
9 four (T2), week six (T3), week eight (T4) week ten (T5) and so on until week twenty (T10)).  
10 Two follow ups are planned: FU1 after six month and FU2 after one year after study entry.  
11 For follow-up assessments (FU1 and FU2), patients and their guardians will be informed and  
12 invited by letter and telephone to participate.  
13  
14

15  
16 The amount and the content of physical rehabilitation, activities of daily life such as the  
17 ability to walk will be documented every day by physiotherapists and occupational therapist  
18 using predefined sheets [16]. All assessments and standardized measures will be administered  
19 by trained and experienced assessors or therapists in the hospital and/or inpatient  
20 rehabilitation, at home or residence facility. **Additionally, we will try to get all information**  
21 **about the content and duration of physiotherapy and or physical rehabilitation applied**  
22 **at all stages of illness.**  
23  
24  
25  
26  
27  
28

Formatted: Font: Bold

### 29 Measures and Outcomes

30 Primary outcomes of the GYMNAST study are walking ability and ability to stand up alone.

31  
32 To measure walking ability the Functional Ambulation Categories (FAC) is used [20]. The  
33 ability to stand up alone will be measured by the ability to stand up from a chair  
34 independently, STS (standardised chair height is defined with 120% of knee height).  
35  
36  
37

38 Secondary outcomes includes

- 39 • Richmond Agitation-Sedation Scale (RASS) [19]
- 40
- 41 • activities measured with the Barthel Index (BI; 10 items) [21]
- 42
- 43 • muscle strength of the upper (shoulder, elbow and wrist) and lower limb (hip, knee  
44 and ankle) using the Medical Research Council (MRC) [1 22]
- 45
- 46 • grip strength **(measured bilaterally using a dynamometer)** [23 24]
- 47
- 48 • Functional Status Score for the Intensive Care Unit Scored (FSS-ICU) [25]
- 49
- 50 • Physical Function –ICU Test (PFIT) [26] and Physical Function –ICU Test- Scored  
51 (PFIT-S) [27]
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

Formatted: Font: Bold

- Pain using a visual analogue scale
- Lateral and frontal sit and stance balance (functional reach) [28 29]
- cognitive measures (Montreal Cognitive Assessment (MoCA) [30] and clock drawing test (CDT) [31]
- walking ability (0-5; FAC) [32], walking speed (we will use a 10m walking test, adopting a 14-m course and will measure the walking speed over the central 10 m) and walking endurance (we will use a six minute walking test, using 40m course and will measure the distance walked in six minutes; if patients cannot walk the whole six minutes we will measure the maximum walking distance here) [5 6]
- quality of life (EQ-5D) [33]
- participation (Reintegration to Normal Living, RNL-Index) [34 35]
- fitness and mobility (PASIPD) [36 37]

Formatted: Font: Bold

Formatted: Font: Bold

Formatted: Font: Bold

Formatted: Font: Bold

Formatted: Font: Bold

All measures chosen are frequently used in research and/or daily clinical practice dealing with the above described patients.

The primary outcome variables FAC and STS will be measured daily with standardized sheets for this purpose.

At baseline assessment (T0) and then every two weeks until twenty weeks after baseline (T10) we will assess RASS, BI, muscle strength of the upper and lower limb (MRC), grip strength, FSS-ICU, PFIT and PFIT-S, pain, functional reach, cognitive measures, walking speed and endurance.

At follow ups FU1 after six month and FU2 after one year after study entry we will measure the EQ-5D, the RNL-Index and PASIPD. Additionally we will be gathering detailed survival data.

Tables 1 gives a detailed overview of the variables used at each time point of study.

#### Possible clinical prognostic factors

1  
2  
3  
4  
5  
6  
7 Depending on the primary outcomes (walking ability and activities), a range of potentially  
8 prognostic factors will be taken into account. These factors include: demographic variables  
9 (such as age, sex), clinical variables (such as FSS-ICU, PFIT-S) and medical characteristics  
10 (such as **diagnoses, reason for ICU-treatment, duration of mechanical ventilation,**  
11 **duration of illness) and anthropometric measures, such as body weight and body mass**  
12 **index (but not limb circumference).**

Formatted: Font: Bold

### 13 14 15 16 17 18 Planned statistical analyses

19  
20 We will use descriptive analyses, e.g. means and standard deviations of the continuous  
21 variables and frequencies and proportions of categorical variables as appropriate [38]. We will  
22 explain differences across the time points (T1–T10 and FU1 - FU2) descriptively and with  
23 appropriate inference statistics use parametric and non-parametric tests as appropriate e.g.  
24 repeated measures analysis of variance [38]. The global alpha level will be set at 0.05.  
25  
26

27  
28 Time to regain walking ability and time to stand up from a chair independently will be the  
29 main end point for this analysis. The following factors will be analyzed for their association  
30 with these endpoints:  
31

- 32 • demographic variables (such as age and sex),
- 33 • clinical variables (such as muscle strength, FSS-ICU, PFIT-S) and
- 34 • medical characteristics (such as diagnosis and duration of illness)

35  
36  
37  
38  
39 The probability in regaining walking ability and sit to stand ability will be calculated with the  
40 method of Kaplan and Meier [39]. Cox regression analysis will be used to estimate relative  
41 hazard rates and to test for differences in variables or trends in subgroups of each factor [40].  
42 A stepwise multivariable Cox regression analysis will be applied with a variable selection [40  
43 41].  
44

45  
46  
47 Time to event or censoring will be defined as time difference between study entry (T0) and  
48 date of reaching a FAC score equal to 3, or the possible censoring dates of discharge or dead,  
49 respectively. Possible prognostic factors from demographic, clinical and medical variables  
50 will be selected for a multivariable model based on clinical and statistical significance [42-  
51 44]. The final model selection will be performed based on clinical decision, together with  
52 Akaike's information criterion (AIC) and the Bayesian information criterion (BIC) [41]. Aim  
53  
54  
55  
56  
57  
58  
59  
60

of our analysis is to *explain* the dependent variable (regaining walking function) by a multivariate Cox proportional hazard model with not too many variables.

To prevent overfitting, only variables with clinically important *and* statistically significant bivariate association with our endpoint will be included in the final model [41].

The effects of prognostic factors in the final model will be expressed as hazard ratios (HR) with 95% confidence intervals (CI) after a graphical assessment of proportionality of hazards.

We will use SAS/STAT 9.3 for all statistical procedures (SAS Institute Inc., Cary, NC, USA).

The proportional hazards assumption will be tested with the implemented function (proc phreg).

## Results

We will describe the demographic and clinical characteristics at each of the individual time points (T1–T10 and FU1 - FU2) descriptively. We will describe the probability in regaining walking ability and other activities with the method of Kaplan and Meier. We will present the final statistical multivariate model for regaining walking ability.

### Sample size and power calculation

The sample size needed in the GymNAST study is calculated using the method for one of the most cited recommendation for prognostic research: the ‘rule of ten events per variable (EPV)’ [13 14 44]. Based on our sample size calculation using the EPV-approach approximately 150 patients will be recruited from the intensive care unit of our long term intensive care hospital in Germany [15]. We anticipate reaching this study size over the time course of three years. Our confidence results from a cross-sectional study. We found a point prevalence of 88 patients per month of people with ICU-acquired muscle weakness and defined diagnosis of CIM/CIP in our intensive care units [16]. Therefore, based on this pilot study it seems to be a realistically to reach the estimated sample size in our cohort study within three years of recruitment.

## **Ethics and Dissemination**

### Ethical considerations



1  
2  
3  
4  
5  
6  
7 The GymNAST study will be conducted in accordance with the 'Helsinki Declaration'. The  
8 study is non-invasive, imposes no risk on patients, seems to have enough power to detect  
9 meaningful determinants and our protocol has been approved by the medical ethical  
10 committees. Furthermore, written informed consent is obtained from all participants or if  
11 necessary from its legal guardian. The study will be registered before publication.  
12  
13

#### 14 Dissemination

15  
16 The results obtained will be disseminated to the scientific, medical and general public by  
17 publication in national and international peer-reviewed journals, as well as by presentations in  
18 conferences and meetings with clinicians dealing with patients with ICU-acquired muscle  
19 weakness syndrome.  
20  
21  
22  
23  
24

#### 25 **Discussion**

26  
27 The GymNAST study will be one of the first studies with rigorous repeated measures over the  
28 time course of one year with daily documentation of rehabilitation therapies of people with  
29 ICU-acquired muscle weakness. Also a wide range of functional variables to describe the  
30 pattern of regaining of walking is used.  
31  
32  
33

34 Until now many prognostic studies including people with ICU-acquired muscle weakness  
35 used rather a traditional prognostic design using a baseline test and compared with ICU  
36 discharge and follow-ups [5 26 27] and only some studies measures continuously over time  
37 [45]. However, instead of comparing two or more measurements of the patient's performance  
38 it seems to be more informative to analyze the dynamic recovery systematically using equal  
39 time intervals over an appropriate time period e.g. with daily assessments of walking function  
40 and with daily description of physical rehabilitation over months. This might provide a more  
41 detailed understanding of the pattern and the dynamics of recovery of walking function, and  
42 allows a better understanding of changes in clinical characteristics and the applied  
43 rehabilitation therapies.  
44  
45  
46  
47  
48

49 Also, detailed knowledge about the time course of recovery of walking ability, their risks and  
50 chances (e.g. clinical and therapeutic determinants) are still not very well understood. The  
51 present study documents clinical determinants at equal time intervals (every two weeks) and  
52 will document therapeutic determinants daily.  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Strong aspects of GymNAST are therefore its prospective design with multiple repeated assessments during the first year after illness using equal time intervals of people with ICU-acquired muscle weakness. The present study might therefore provide new and more detailed information about the pattern of walking recovery and the physical rehabilitation content of people with ICU-acquired muscle weakness.

A potential limitation of the study is that the most seriously affected patients might be unable to participate, thereby reducing the possibility to generalize the results to the whole critical ill population. Another limitation might be that no objective measures for muscle weakness such as electromyography or magnetic resonance tomography will be used.

**Authors' contributions:**

J.M., S.M, FO and M.P. planned the study. F.O. and M.P. contributed to the procurement of funding. J.M., S.M, and M.P. developed the protocol. All authors contributed to and checked the final draft of the manuscript.

**Funding statement:**

This study is financially supported by the Centre of Research from Klinik Bavaria, Kreischa, Germany and by the Department of Public Health, Medizinische Fakultät ,Carl Gustav Carus', Technische Universität Dresden, Germany

**Competing interests statement:**

None declared

**Literatur**

1. Nordon-Craft A, Moss M, Quan D, Schenkman M. Intensive Care Unit-Acquired Weakness. *Phys Ther* 2012;92(12):1494-506.
2. Fan E. Critical illness neuromyopathy and the role of physical therapy and rehabilitation in critically ill patients. *Respir Care* 2012;57(6):933-44; discussion 944-6.
3. Herridge MS. The challenge of designing a post-critical illness rehabilitation intervention. *Crit Care* 2011;15(5):1002.
4. Ohtake PJ, Strasser DC, Needham DM. Rehabilitation for people with critical illness: taking the next steps. *Physical Therapy* 2012;92(12):1484-8.
5. Herridge MS, Cheung AM, Tansey CM, Matte-Martyn A, Diaz-Granados N, Al-Saidi F, et al. One-year outcomes in survivors of the acute respiratory distress syndrome. *N Engl J Med* 2003;348(8):683-93.
6. Herridge MS, Tansey CM, Matte A, Tomlinson G, Diaz-Granados N, Cooper A, et al. Functional disability 5 years after acute respiratory distress syndrome. *N Engl J Med* 2011;364(14):1293-304.
7. Hermans G, De Jonghe B, Bruyninckx F, Van den Berghe G. Clinical review: critical illness polyneuropathy and myopathy. *Critical Care*, 2008:238.
- 8. Kress J, Hall J. ICU-acquired weakness and recovery from critical illness. *N Engl J Med* 2014;370(17):1626-35.**
9. Denehy L, Berney S, Skinner E, Edbrook L, Warrillow S, Hawthorne G, et al. Evaluation of Exercise Rehabilitation for Survivors of Intensive Care: Protocol for Single Blind Randomised Controlled Trial. *The Open Critical Care Medicine Journal* 2008;1:39-47.
10. Denehy L, Berney S, Skinner E, Edbrooke L, Warrillow S, Hawthorne G, et al. Evaluation of exercise rehabilitation for survivors of intensive care: protocol for single blind randomised controlled trial. *Open Critical Care Medicine Journal*, 2008:39-47.
11. Denehy L, Skinner EH, Edbrooke L, Haines K, Warrillow S, Hawthorne G, et al. Exercise rehabilitation for patients with critical illness: a randomized controlled trial with 12 months follow up. *Crit Care* 2013;17(4):R156.
12. Nordon-Craft A, Schenkman M, Ridgeway K, Benson A, Moss M. Physical therapy management and patient outcomes following ICU-acquired weakness: a case series. *J Neurol Phys Ther* 2011;35(3):133-40.

Formatted: Font: Bold

13. Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. *J Clin Epidemiol* 1995;48(12):1503-10.
14. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. *Am J Epidemiol* 2007;165(6):710-8.
15. Mallett S, Royston P, Dutton S, Waters R, Altman DG. Reporting methods in studies developing prognostic models in cancer: a review. *BMC Med* 2010;8:20.
16. Mückel S, Mehrholz K, Mehrholz J, Pohl M. Treatment approaches of patients with ICU acquired weakness [Behandlungsansätze bei Patienten mit auf der Intensivstation erworbenen Schwächesyndrom]. *Neuroreha* 2013;5(1):40-43.
17. Latronico N, Rasulo FA. Presentation and management of ICU myopathy and neuropathy. *Curr Opin Crit Care* 2010;16(2):123-7.
18. Latronico N, Bolton C. Critical illness polyneuropathy and myopathy: a major cause of muscle weakness and paralysis. *Lancet Neurology* 2011;10(10):931-41.
19. Sessler CN, Gosnell MS, Grap MJ, Brophy GM, O'Neal PV, Keane KA, et al. The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients. *Am J Respir Crit Care Med* 2002;166(10):1338-44.
20. Holden MK, Gill KM, Magliozzi MR. Gait assessment for neurologically impaired patients. Standards for outcome assessment. *Phys Ther* 1986;66(10):1530-9.
21. Mahoney FI, Barthel DW. Functional Evaluation: The Barthel Index. *Md State Med J* 1965;14:61-5.
22. Kleyweg RP, van der Meche FG, Schmitz PI. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barre syndrome. *Muscle Nerve* 1991;14(11):1103-9.
23. Mathiowetz V, Weber K, Volland G, Kashman N. Reliability and validity of grip and pinch strength evaluations. *J Hand Surg Am* 1984;9(2):222-6.
24. Mathiowetz V, Kashman N, Volland G, Weber K, Dowe M, Rogers S. Grip and pinch strength: normative data for adults. *Arch Phys Med Rehabil* 1985;66(2):69-74.
25. Zanni JM, Korupolu R, Fan E, Pradhan P, Janjua K, Palmer JB, et al. Rehabilitation therapy and outcomes in acute respiratory failure: an observational pilot project. *J Crit Care* 2010;25(2):254-62.
26. Nordon-Craft A, Schenkman M, Edbrooke L, Malone DJ, Moss M, Denehy L. The Physical Function Intensive Care Test: Implementation in Survivors of Critical Illness. *Phys Ther* 2014.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

27. Denehy L, de Morton N, Skinner E, Edbrooke L, Haines K, Warrillow S, et al. A Physical Function Test for Use in the Intensive Care Unit: Validity, Responsiveness, and Predictive Utility of the Physical Function in Intensive Care Test (Scored). *Phys Ther* 2013;93(12):1636-45.
28. Weiner DK, Duncan PW, Chandler J, Studenski SA. Functional reach: a marker of physical frailty. *J Am Geriatr Soc* 1992;40(3):203-7.
29. Newton RA. Validity of the multi-directional reach test: a practical measure for limits of stability in older adults. *J Gerontol A Biol Sci Med Sci* 2001;56(4):M248-52.
30. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc* 2005;53(4):695-9.
31. Ismail Z, Rajji TK, Shulman KI. Brief cognitive screening instruments: an update. *Int J Geriatr Psychiatry* 2010;25(2):111-20.
32. Holden MK, Gill KM, Magliozzi MR, Nathan J, Piehl-Baker L. Clinical gait assessment in the neurologically impaired. Reliability and meaningfulness. *Phys Ther* 1984;64(1):35-40.
33. EuroQol-Group. EuroQol--a new facility for the measurement of health-related quality of life. *Health Policy* 1990;16(3):199-208.
34. Wood-Dauphinee SL, Opzoomer MA, Williams JI, Marchand B, Spitzer WO. Assessment of global function: The Reintegration to Normal Living Index. *Arch Phys Med Rehabil* 1988;69(8):583-90.
35. Wood-Dauphinee S, Williams JI. Reintegration to Normal Living as a proxy to quality of life. *J Chronic Dis* 1987;40(6):491-502.
36. Salisbury LG, Merriweather JL, Walsh TS. Rehabilitation after critical illness: could a ward-based generic rehabilitation assistant promote recovery? *Nurs Crit Care* 2010;15(2):57-65.
37. van den Berg-Emons RJ, L'Ortye AA, Buffart LM, Nieuwenhuijsen C, Nooijen CF, Bergen MP, et al. Validation of the Physical Activity Scale for individuals with physical disabilities. *Arch Phys Med Rehabil* 2011;92(6):923-8.
38. Armitage P, Colton T. *Encyclopedia of Biostatistics*. Chichester: Wiley, 1998.
39. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. *Journal of the American Statistical Association* 1958;53(282):457-481.
40. Kleinbaum D, Klein M. *Survival Analysis. A Self-Learning Text*. 3rd ed. New York: Springer, 2012.

- 1  
2  
3  
4  
5  
6  
7 41. Hosmer D, Lemeshow S, May S. *Applied Survival Analysis: Regression Modeling of Time*  
8 *to Event Data*. 2nd ed. New York: John Wiley & Sons, Inc., 2008.  
9  
10 42. Spiegelhalter DJ. Probabilistic prediction in patient management and clinical trials. *Stat*  
11 *Med* 1986;5(5):421-33.  
12  
13 43. Steyerberg EW, Eijkemans MJ, Harrell FE, Jr., Habbema JD. Prognostic modelling with  
14 logistic regression analysis: a comparison of selection and estimation methods in small  
15 data sets. *Stat Med* 2000;19(8):1059-79.  
16  
17 44. Hosmer DW, Lemeshow S. *Applied Logistic Regression*. 2ed ed. New York: John Wiley  
18 & Sons, Inc., 2000.  
19  
20 45. Schweickert WD, Pohlman MC, Pohlman AS, Nigos C, Pawlik AJ, Esbrook CL, et al.  
21 Early physical and occupational therapy in mechanically ventilated, critically ill  
22 patients: a randomised controlled trial. *Lancet*, 2009:1874-82.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1** Summary of outcome measures and time points of assessment in GymNAST

	Baseline	Daily	Biweekly (T1 to T12)	Follow-up (FU 1 and 2)
<b>Amount and content of Physical Rehabilitation</b>				
Physiotherapy		x		x
Occupational Therapy		x		x
Other therapies (e.g. groups)		x		x
<b>Primary Outcome</b>				
FAC and STS	x	x		
<b>Delir measures</b>				
RASS	x		x	
<b>Strength measures</b>				
MRC score	x		x	x
Grip strength	x		x	x
<b>Physical function measures</b>				
PFIT and PFIT-S	x		x	x
FSS-ICU score	x		x	x
10m walking time	x		x	x
6-MWT	x		x	x
Pain (VAS)	x		x	x
functional reach	x		x	x
<b>Cognition measures</b>				
MOCA	x		x	x
CDT	x		x	x
<b>Activities and Mobility</b>				
BI	x		x	x
PASIPD				x
<b>Participation and quality of life</b>				
EQ-5D				x
RNL-Index				x



1  
2  
3  
4  
5  
6  
7 **Abbreviations: GymNAST: General Weakness Syndrome Therapy study; FU= Follow**  
8 **Up; T= Time point; FAC: Functional Ambulation; STS: ability to stand up from a chair**  
9 **independently; RASS: Richmond Agitation-Sedation Scale; MRC: Medical Research**  
10 **Council (muscle strength of the upper (shoulder, elbow and wrist) and lower limb (hip,**  
11 **knee and ankle)); PFIT: Physical Function –Intensive Care Unit- Test; PFIT-S: Physical**  
12 **Function – Intensive Care Unit Test- Scored; FSS-ICU: Functional Status Score for the**  
13 **Intensive Care Unit Scored; 6-MWT: six minute walking test; VAS: visual analogue**  
14 **scale; MOCA= Montreal Cognitive Assessment; CDT: clock drawing test; BI: Barthel**  
15 **Index; PASIPD: Physical Activity Scale for Individuals with Physical Disabilities; EQ-**  
16 **5D: EuroQol (5 dimensions); RNL-Index: Reintegration to Normal Living Index**  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Formatted: Font: Bold

# BMJ Open

## The General Weakness Syndrome Therapy (GymNAST) study: protocol for a cohort study on recovery on walking function.

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-006168.R2
Article Type:	Protocol
Date Submitted by the Author:	08-Sep-2014
Complete List of Authors:	Mehrholz, Jan; Technische Universität Dresden, Department of Public Health, Medizinische Fakultät ‚Carl Gustav Carus‘ Mückel, Simone; Private Europäische Medizinische Akademie der Klinik Bavaria in Kreischa, Wissenschaftliches Institut Oehmichen, Frank; Klinik Bavaria Kreischa, Fach und Privatkrankenhaus Pohl, Marcus; Klinik Bavaria Kreischa, Fach und Privatkrankenhaus
<b>Primary Subject Heading</b>:	Intensive care
Secondary Subject Heading:	Evidence based practice, Rehabilitation medicine
Keywords:	Adult intensive & critical care < ANAESTHETICS, REHABILITATION MEDICINE, Adult neurology < NEUROLOGY

SCHOLARONE™  
Manuscripts

1  
2  
3 **The General Weakness Syndrome Therapy (GymNAST) study: protocol for a cohort**  
4 **study on recovery on walking function.**  
5

6  
7 Jan Mehrholz<sup>1,3\*</sup>, Simone Mückel<sup>1</sup>, Frank Oehmichen<sup>2</sup> and Marcus Pohl<sup>2</sup>  
8

9  
10 <sup>1</sup> *Wissenschaftliches Institut, Private Europäische Medizinische Akademie der Klinik Bavaria*  
11 *in Kreischa, An der Wolfsschlucht 1-2, 01731 Kreischa, Germany*  
12

13  
14 <sup>2</sup> *Fach und Privatkrankenhaus, Klinik Bavaria in Kreischa, An der Wolfsschlucht 1-2, 01731*  
15 *Kreischa, Germany*  
16

17  
18 <sup>3</sup> *Department of Public Health, Medizinische Fakultät, Carl Gustav Carus, Technische*  
19 *Universität Dresden, Germany*  
20

21  
22 **\*Corresponding author**  
23

24 Prof. Dr. Jan Mehrholz, Wissenschaftliches Institut, Private Europäische Medizinische  
25 Akademie der Klinik Bavaria in Kreischa GmbH, An der Wolfsschlucht 1-2, 01731 Kreischa,  
26 Germany  
27  
28

29  
30 Tel: ++49 35206 62054  
31

32  
33 Fax: ++49 35206 63517  
34

35 [jan.mehrholz@klinik-bavaria.de](mailto:jan.mehrholz@klinik-bavaria.de)  
36  
37

38  
39  
40 Short title: Study protocol: General Weakness Syndrome Therapy  
41

42  
43 Keywords: intensive care - rehabilitation - walking - muscle weakness  
44

45  
46 Word count: 4 623  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

Introduction: Critical illness myopathy (CIM) and polyneuropathy (CIP) are common complications of critical illness that frequently occur together. Both cause so called intensive-care-unit-acquired (ICU)-acquired muscle weakness. This weakness of limb muscles increases morbidity and delay rehabilitation and recovery of walking ability. Although full recovery has been reported people with severe weakness may take months to improve walking. Focused physical rehabilitation of people with ICU-acquired muscle weakness is therefore of great importance.

However, although physical rehabilitation is common, detailed knowledge about the pattern and the time course of recovery of walking function are not well understood.

Therefore the aim of the General Weakness Syndrome Therapy (GymNAST) study is to describe the time course of recovery of walking function and other activities of daily living in these patients.

Methods and analysis: We conduct a prospective cohort study of people with ICU-acquired muscle weakness with defined diagnosis of CIM or CIP.

Based on our sample size calculation, approximately 150 patients will be recruited from the intensive care unit of our hospital in Germany. Amount and content of physical rehabilitation, clinical tests e.g. muscle strength and motor function and neuropsychological assessments will be used as independent variables. The primary outcomes will include recovery of walking function and mobility. Secondary outcomes will include global motor function, activities in daily life and participation.

Ethics and dissemination: The study is being carried out in agreement with the Declaration of Helsinki and conducted with the approval of the local medical Ethics Committee (Landesärztekammer Sachsen, Germany, reference number EK-BR-32/13-1) and with the understanding and written consent of each patient's guardian.

The results of this study will be published in peer-reviewed journals and disseminated to the medical society and general public.

## Article Summary

### Article focus:

The aim of the General Weakness Syndrome Therapy (GymNAST) study is to determine the time course of recovery of walking function, to describe the detailed content of physical rehabilitation and also to describe possible risk factors and chances for recovery of walking function in the first year after ICU-acquired muscle weakness.

### Key messages:

This study will determine how people with ICU-acquired muscle weakness are related to clinical characteristics and describe the time course of motor and cognitive performance and activities of daily life.

The results will be of interest of clinicians working with critical ill patients and will give insights into the black box of rehabilitation and its impact on recovery of ICU-acquired muscle weakness due to CIM/CIP. The results of this study may therefore inform patients and their caregivers, therapists working in rehabilitation to choose the most appropriate treatment, and to develop adapted rehab programs.

### Strengths and limitations:

The strength of this study is that it is one of the first prospective cohort studies in the first year of ICU-acquired muscle weakness with daily documentation of physical rehabilitation and walking function. Multiple repeated assessments, with a wide range of clinical measures will be done. Such a measurement design has several advantages compared to other prognostic studies done so far using just two measurements in time. Our longitudinal repeated measure design may provide further insights into dynamics of recovery of walking function and other activities over the first year of people with ICU-acquired muscle weakness.

One limitation could be that most severe affected patients have to be excluded in this study. This may reduce the generalisability of the results to the whole population critical ill patients. Another limitation might be that no objective measures for muscle weakness such as electromyography or magnetic resonance tomography will be used.

## Introduction

Critical illness myopathy (CIM) and polyneuropathy (CIP) are common complications of critical illness that frequently occur together. Both cause so called intensive-care-unit-acquired (ICU)-acquired muscle weakness. According to Norton-Craft this weakness is characterized by a profound weakness that is greater than might be expected to result from prolonged bed rest [1]. The weakness of limb muscles limits significantly activities and assistance for basic activities such as sit-to stand or sitting and standing is oftentimes required [2-4]. This increases morbidity and delays rehabilitation and recovery of walking [5 6]. Although full recovery has been reported in approximately 50% of people with ICU-acquired muscle weakness, improvement is related to the severity of the condition e.g. people with severe weakness may take months to improve, or even remain severely affected [7 8]. Focused physical rehabilitation of people with ICU-acquired muscle weakness is therefore of great importance. There is practical evidence that physical rehabilitation of patients can be implemented with few adverse effects [1]. In recent years appropriate assessments were developed and description of suitable physical intervention strategies were described in the literature [1 8-12].

However, detailed knowledge about the time course of recovery of walking and other activities, their risk factors and chances for good recovery such are not well described or understood. Furthermore it lacks on detailed description of physical rehabilitation and on a repeated measure cohort study in the first year of people with ICU-acquired muscle weakness. Such a design would give better insights in to the time course of recovery of walking function and activities of these patients.

Therefore the aim of the General Weakness Syndrome Therapy (GymNAST) study is to describe and to identify time course and the pattern of recovery of walking, motor functions and of activities of daily living in these patients. Other aims are to describe the detailed content of physical rehabilitation and to develop a multivariate model of risk factors for recovery of walking function in the first year of ICU-acquired muscle weakness.

Here we describe the design and protocol of the GymNAST study, which is an appropriate large prospective cohort study of critical ill people with ICU-acquired muscle weakness including a detailed description of physical rehabilitation contents. This study will help to understand the time course and pattern of recovery of walking function and of activities of

1  
2  
3 daily live. Furthermore a multivariate model for recovery of walking ability will be  
4 developed.  
5  
6

## 7 **Methods and analysis**

### 8 Study objectives

9  
10  
11 The primary objective of the GymNAST study is to assess the time course of regaining  
12 walking and sit to stand ability as important activities of daily live  
13  
14

15  
16 Secondary objectives are to:

- 17 • describe the concomitant physical rehabilitation therapies
- 18
- 19 • describe the clinical course of recovery using standardized outcome measures and their
- 20 results
- 21
- 22 • identify a prognostic model for regain walking and sit to stand abilities
- 23
- 24
- 25
- 26
- 27
- 28
- 29

### 30 Design

31  
32 We conduct a prospective cohort study of people with ICU-acquired muscle weakness and  
33 defined diagnosis of CIM/CIP. We started in 2013 and the final assessments including follow  
34 up will be made in 2015.  
35  
36

37  
38 Based on our sample size calculation [13 14], approximately 150 patients will be recruited  
39 from a intensive care unit of our hospital in Germany [15] over the time course of three years.  
40 In a first cross sectional pilot study in our hospital we found a point prevalence of 88 patients  
41 with defined diagnosis of CIM/CIP and ICU-acquired muscle weakness per month [16].  
42 Therefore, based on this pilot study it seems to be realistically to reach the anticipated sample  
43 size in our cohort study within three years of recruitment.  
44  
45  
46  
47  
48

### 49 Study population

50  
51 Patients with ICU-acquired muscle weakness and defined diagnosis of CIM/CIP will be  
52 recruited consecutively from the intensive care units of our acute care, weaning and early  
53 rehabilitation centers of Klinik Bavaria Kreischa in Germany.  
54  
55  
56

### 57 Inclusion criteria

- patient is chronic critical ill or has a contemporary history of chronic critical ill defined as more than 21 days ICU-treatment including mechanical ventilation and at least 14 days further existing critical situation with the need for ICU-treatment [17]
- defined diagnosis of Critical illness myopathy (CIM) and polyneuropathy (CIP). The diagnosis of CIM/CIP will be confirmed by a neurologist. Therefore, clinical and neurophysiologic data will be revealed. The procedure of diagnosis of CIP and CIM is described in detail elsewhere [18-20]
- muscle weakness defined as a Medical Research Council (MRC) sum score of less than 48 points [1]
- more than 18 years old
- Richmond Agitation Sedation Scale (RASS) score from -1 to 2 [21]
- written informed consent of the patient or his legal guardian

#### Exclusion criteria

- Patients receiving palliative care
- Co-morbidities of the trunk or the lower limbs interfering with upright posture and walking function (e.g. Amputation or fracture of lower limb)
- Other neuromuscular or neurological disease and/or syndromes causing weakness in patients in the ICU (we will exclude patients with diseases and syndromes causing weakness in patients in the ICU[8], due to Guillain–Barré syndrome, myasthenia gravis, porphyria, Eaton–Lambert syndrome, amyotrophic lateral sclerosis, vasculitic neuropathy, cervical myelopathy and botulism)
- severe physical co-morbidity before becoming critical ill (e.g, frailty due to neurological conditions)

#### Procedure

Eligible patients will be screened and afterwards will get oral and written information about the study from their treating physician or researcher. After written informed consent the demographic and clinical characteristics will be measured (baseline assessment T0). Patients



1  
2  
3 will then be measured every two weeks after baseline up to 20 weeks (week two (T1), week  
4 four (T2), week six (T3), week eight (T4) week ten (T5) and so on until week twenty (T10)).  
5 Two follow ups are planned: FU1 after six month and FU2 after one year after study entry.  
6 For follow-up assessments (FU1 and FU2), patients and their guardians will be informed and  
7 invited by letter and telephone to participate.  
8  
9

10  
11 The amount and the content of physical rehabilitation, activities of daily life such as the  
12 ability to walk will be documented every day by physiotherapists and occupational therapist  
13 using predefined sheets [16]. All assessments and standardized measures will be administered  
14 by trained and experienced assessors or therapists in the hospital and/or inpatient  
15 rehabilitation, at home or residence facility. Additionally, we will try to get all information  
16 about the content and duration of physiotherapy and or physical rehabilitation applied at all  
17 stages of illness.  
18  
19  
20  
21  
22  
23

### 24 25 26 27 Measures and Outcomes

28  
29 Primary outcomes of the GYMNAST study are walking ability and ability to stand up alone.  
30

31  
32 To measure walking ability the Functional Ambulation Categories (FAC) is used [22]. The  
33 ability to stand up alone will be measured by the ability to stand up from a chair  
34 independently, STS (standardised chair height is defined with 120% of knee height).  
35  
36

37  
38 Secondary outcomes includes

- 39  
40 • Richmond Agitation-Sedation Scale (RASS) [21]
- 41  
42 • activities measured with the Barthel Index (BI; 10 items) [23]
- 43  
44 • muscle strength of the upper (shoulder, elbow and wrist) and lower limb (hip, knee  
45 and ankle) using the Medical Research Council (MRC) [1 24]
- 46  
47 • grip strength (measured bilaterally using a dynamometer) [25 26]
- 48  
49 • Functional Status Score for the Intensive Care Unit Scored (FSS-ICU) [27]
- 50  
51 • Physical Function –ICU Test (PFIT) [28] and Physical Function –ICU Test- Scored  
52 (PFIT-S) [29]
- 53  
54 • Pain using a visual analogue scale  
55  
56  
57  
58  
59  
60

- Lateral and frontal sit and stance balance (functional reach) [30 31]
- cognitive measures (Montreal Cognitive Assessment (MoCA) [32] and clock drawing test (CDT) [33])
- walking ability (0- 5; FAC) [34], walking speed (we will use a 10m walking test, adopting a 14-m course and will measure the walking speed over the central 10 m) and walking endurance (we will use a six minute walking test, using 40m course and will measure the distance walked in six minutes; if patients cannot walk the whole six minutes we will measure the maximum walking distance here) [5 6]
- quality of life (EQ-5D) [35]
- participation (Reintegration to Normal Living, RNL-Index) [36 37]
- fitness and mobility (PASIPD) [38 39]

All measures chosen are frequently used in research and/or daily clinical practice dealing with the above described patients.

The primary outcome variables FAC and STS will be measured daily with standardized sheets for this purpose.

At baseline assessment (T0) and then every two weeks until twenty weeks after baseline (T10) we will assess RASS, BI, muscle strength of the upper and lower limb (MRC), grip strength, FSS-ICU, PFIT and PFIT-S, pain, functional reach, cognitive measures, walking speed and endurance.

At follow ups FU1 after six month and FU2 after one year after study entry we will measure the EQ-5D, the RNL-Index and PASIPD. Additionally we will be gathering detailed survival data.

Tables 1 gives a detailed overview of the variables used at each time point of study.

#### Possible clinical prognostic factors

Depending on the primary outcomes (walking ability and activities), a range of potentially prognostic factors will be taken into account. These factors include: demographic variables (such as age, sex), clinical variables (such as FSS-ICU, PFIT-S) and medical characteristics

1  
2  
3 (such as diagnoses, reason for ICU-treatment, duration of mechanical ventilation, duration of  
4 illness) and anthropometric measures, such as body weight and body mass index (but not limb  
5 circumference).  
6  
7  
8  
9

### 10 11 Planned statistical analyses

12  
13 We will use descriptive analyses, e.g. means and standard deviations of the continuous  
14 variables and frequencies and proportions of categorical variables as appropriate [40]. We will  
15 explain differences across the time points (T1–T10 and FU1 - FU2) descriptively and with  
16 appropriate inference statistics use parametric and non-parametric tests as appropriate e.g.  
17 repeated measures analysis of variance [40]. The global alpha level will be set at 0.05.  
18  
19

20  
21 Time to regain walking ability and time to stand up from a chair independently will be the  
22 main end point for this analysis. The following factors will be analyzed for their association  
23 with these endpoints:  
24  
25  
26

- 27 • demographic variables (such as age and sex),
  - 28 • clinical variables (such as muscle strength, FSS-ICU, PFIT-S) and
  - 29 • medical characteristics (such as diagnosis and duration of illness)
- 30  
31  
32  
33  
34  
35

36 The probability in regaining walking ability and sit to stand ability will be calculated with the  
37 method of Kaplan and Meier [41]. Cox regression analysis will be used to estimate relative  
38 hazard rates and to test for differences in variables or trends in subgroups of each factor [42].  
39 A stepwise multivariable Cox regression analysis will be applied with a variable selection [42  
40 43].  
41  
42  
43  
44

45 Time to event or censoring will be defined as time difference between study entry (T0) and  
46 date of reaching a FAC score equal to 3, or the possible censoring dates of discharge or dead,  
47 respectively. Possible prognostic factors from demographic, clinical and medical variables  
48 will be selected for a multivariable model based on clinical and statistical significance [44-  
49 51]. The final model selection will be performed based on clinical decision, together with  
50 Akaike's information criterion (AIC) and the Bayesian information criterion (BIC) [43]. Aim  
51 of our analysis is to *explain* the dependent variable (regaining walking function) by a  
52 multivariate Cox proportional hazard model with not too many variables.  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 To prevent overfitting, only variables with clinically important *and* statistically significant  
4 bivariate association with our endpoint will be included in the final model [43].  
5  
6

7 The effects of prognostic factors in the final model will be expressed as hazard ratios (HR)  
8 with 95% confidence intervals (CI) after a graphical assessment of proportionality of hazards.  
9  
10

11 We will use SAS/STAT 9.3 for all statistical procedures (SAS Institute Inc., Cary, NC, USA).  
12 The proportional hazards assumption will be tested with the implemented function (proc  
13 phreg).  
14  
15  
16  
17  
18

## 19 Results

20  
21 We will describe the demographic and clinical characteristics at each of the individual time  
22 points (T1–T10 and FU1 - FU2) descriptively. We will describe the probability in regaining  
23 walking ability and other activities with the method of Kaplan and Meier. We will present the  
24 final statistical multivariate model for regaining walking ability.  
25  
26  
27  
28

### 29 Sample size and power calculation

30  
31 The sample size needed in the GymNAST study is calculated using the method for one of the  
32 most cited recommendation for prognostic research: the ‘rule of ten events per variable  
33 (EPV)’ [13 14 46]. Based on our sample size calculation using the EPV-approach  
34 approximately 150 patients will be recruited from the intensive care unit of our long term  
35 intensive care hospital in Germany [15]. We anticipate reaching this study size over the time  
36 course of three years. Our confidence results from a cross-sectional study. We found a point  
37 prevalence of 88 patients per month of people with ICU-acquired muscle weakness and  
38 defined diagnosis of CIM/CIP in our intensive care units [16]. Therefore, based on this pilot  
39 study it seems to be a realistically to reach the estimated sample size in our cohort study  
40 within three years of recruitment.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

## 51 **Ethics and Dissemination**

### 52 Ethical considerations

53  
54 The GymNAST study will be conducted in accordance with the ‘Helsinki Declaration’. The  
55 study is non-invasive, imposes no risk on patients, seems to have enough power to detect  
56  
57  
58  
59  
60

1  
2  
3 meaningful determinants and our protocol has been approved by the medical ethical  
4 committees. Furthermore, written informed consent is obtained from all participants or if  
5 necessary from its legal guardian. The study will be registered before publication.  
6  
7

### 8 Dissemination

9  
10 The results obtained will be disseminated to the scientific, medical and general public by  
11 publication in national and international peer-reviewed journals, as well as by presentations in  
12 conferences and meetings with clinicians dealing with patients with ICU-acquired muscle  
13 weakness syndrome.  
14  
15  
16  
17  
18  
19

### 20 **Discussion**

21  
22 The GymNAST study will be one of the first studies with rigorous repeated measures over the  
23 time course of one year with daily documentation of rehabilitation therapies of people with  
24 ICU-acquired muscle weakness. Also a wide range of functional variables to describe the  
25 pattern of regaining of walking is used.  
26  
27  
28  
29

30  
31 Until now many prognostic studies including people with ICU-acquired muscle weakness  
32 used rather a traditional prognostic design using a baseline test and compared with ICU  
33 discharge and follow-ups [5 28 29] and only some studies measures continuously over time  
34 [47]. However, instead of comparing two or more measurements of the patient's performance  
35 it seems to be more informative to analyze the dynamic recovery systematically using equal  
36 time intervals over an appropriate time period e.g. with daily assessments of walking function  
37 and with daily description of physical rehabilitation over months. This might provide a more  
38 detailed understanding of the pattern and the dynamics of recovery of walking function, and  
39 allows a better understanding of changes in clinical characteristics and the applied  
40 rehabilitation therapies.  
41  
42  
43  
44  
45  
46  
47

48 Also, detailed knowledge about the time course of recovery of walking ability, their risks and  
49 chances (e.g. clinical and therapeutic determinants) are still not very well understood. The  
50 present study documents clinical determinants at equal time intervals (every two weeks) and  
51 will document therapeutic determinants daily.  
52  
53  
54

55  
56 Strong aspects of GymNAST are therefore its prospective design with multiple repeated  
57 assessments during the first year after illness using equal time intervals of people with ICU-  
58  
59  
60

1  
2  
3 acquired muscle weakness. The present study might therefore provide new and more detailed  
4 information about the pattern of walking recovery and the physical rehabilitation content of  
5 people with ICU-acquired muscle weakness.  
6  
7

8  
9 A potential limitation of the study is that the most seriously affected patients might be unable  
10 to participate, thereby reducing the possibility to generalize the results to the whole critical ill  
11 population. Another limitation might be that no objective measures for muscle weakness such  
12 as electromyography or magnetic resonance tomography will be used.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Authors' contributions:**

J.M., S.M, FO and M.P. planned the study. F.O. and M.P. contributed to the procurement of funding. J.M., S.M, and M.P. developed the protocol. All authors contributed to and checked the final draft of the manuscript.

**Funding statement:**

This study is financially supported by the Centre of Research from Klinik Bavaria, Kreischa, Germany and by the Department of Public Health, Medizinische Fakultät ,Carl Gustav Carus', Technische Universität Dresden, Germany

**Competing interests statement:**

None declared

## Literatur

1. Nordon-Craft A, Moss M, Quan D, Schenkman M. Intensive Care Unit-Acquired Weakness. *Phys Ther* 2012;92(12):1494-506.
2. Fan E. Critical illness neuromyopathy and the role of physical therapy and rehabilitation in critically ill patients. *Respir Care* 2012;57(6):933-44; discussion 944-6.
3. Herridge MS. The challenge of designing a post-critical illness rehabilitation intervention. *Crit Care* 2011;15(5):1002.
4. Ohtake PJ, Strasser DC, Needham DM. Rehabilitation for people with critical illness: taking the next steps. *Physical Therapy* 2012;92(12):1484-8.
5. Herridge MS, Cheung AM, Tansey CM, Matte-Martyn A, Diaz-Granados N, Al-Saidi F, et al. One-year outcomes in survivors of the acute respiratory distress syndrome. *N Engl J Med* 2003;348(8):683-93.
6. Herridge MS, Tansey CM, Matte A, Tomlinson G, Diaz-Granados N, Cooper A, et al. Functional disability 5 years after acute respiratory distress syndrome. *N Engl J Med* 2011;364(14):1293-304.
7. Hermans G, De Jonghe B, Bruyninckx F, Van den Berghe G. Clinical review: critical illness polyneuropathy and myopathy. *Critical Care*, 2008:238.
8. Kress J, Hall J. ICU-acquired weakness and recovery from critical illness. *N Engl J Med* 2014;370(17):1626-35.
9. Denehy L, Berney S, Skinner E, Edbrook L, Warrillow S, Hawthorne G, et al. Evaluation of Exercise Rehabilitation for Survivors of Intensive Care: Protocol for Single Blind Randomised Controlled Trial. *The Open Critical Care Medicine Journal* 2008;1:39-47.
10. Denehy L, Berney S, Skinner E, Edbrooke L, Warrillow S, Hawthorne G, et al. Evaluation of exercise rehabilitation for survivors of intensive care: protocol for single blind randomised controlled trial. *Open Critical Care Medicine Journal*, 2008:39-47.
11. Denehy L, Skinner EH, Edbrooke L, Haines K, Warrillow S, Hawthorne G, et al. Exercise rehabilitation for patients with critical illness: a randomized controlled trial with 12 months follow up. *Crit Care* 2013;17(4):R156.
12. Nordon-Craft A, Schenkman M, Ridgeway K, Benson A, Moss M. Physical therapy management and patient outcomes following ICU-acquired weakness: a case series. *J Neurol Phys Ther* 2011;35(3):133-40.



- 1  
2  
3 13. Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent  
4 variable in proportional hazards regression analysis. II. Accuracy and precision of  
5 regression estimates. *J Clin Epidemiol* 1995;48(12):1503-10.  
6  
7
- 8 14. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and  
9 Cox regression. *Am J Epidemiol* 2007;165(6):710-8.  
10
- 11 15. Mallett S, Royston P, Dutton S, Waters R, Altman DG. Reporting methods in studies  
12 developing prognostic models in cancer: a review. *BMC Med* 2010;8:20.  
13
- 14 16. Mückel S, Mehrholz K, Mehrholz J, Pohl M. Treatment approaches of patients with ICU  
15 acquired weakness [Behandlungsansätze bei Patienten mit auf der Intensivstation  
16 erworbenen Schwächesyndrom]. *Neuroreha* 2013;5(1):40-43.  
17
- 18 17. Oehmichen F, Ragaller M. Beatmungsentwöhnung bei Chronisch-Kritisch-Kranken.  
19 *Intensiv- und Notfallbehandlung* 2012;37(3):118-126.  
20
- 21 18. Oehmichen F, Pohl M, Schlosser R, Stogowski D, Toppel D, Mehrholz J. Critical-illness-  
22 Polyneuropathie und -Polymyopathie. Wie sicher ist die klinische Diagnose bei  
23 Patienten mit Weaning-Versagen? [Critical illness polyneuropathy und polymyopathy  
24 : How certain is the clinical diagnosis in patients with weaning failure?]. *Nervenarzt*  
25 2012;83(2):220-225.  
26  
27
- 28 19. Latronico N, Rasulo FA. Presentation and management of ICU myopathy and neuropathy.  
29 *Curr Opin Crit Care* 2010;16(2):123-7.  
30  
31
- 32 20. Latronico N, Bolton C. Critical illness polyneuropathy and myopathy: a major cause of  
33 muscle weakness and paralysis. *Lancet Neurology* 2011;10(10):931-41.  
34  
35
- 36 21. Sessler CN, Gosnell MS, Grap MJ, Brophy GM, O'Neal PV, Keane KA, et al. The  
37 Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit  
38 patients. *Am J Respir Crit Care Med* 2002;166(10):1338-44.  
39  
40
- 41 22. Holden MK, Gill KM, Magliozzi MR. Gait assessment for neurologically impaired  
42 patients. Standards for outcome assessment. *Phys Ther* 1986;66(10):1530-9.  
43  
44
- 45 23. Mahoney FI, Barthel DW. Functional Evaluation: The Barthel Index. *Md State Med J*  
46 1965;14:61-5.  
47  
48
- 49 24. Kleyweg RP, van der Meche FG, Schmitz PI. Interobserver agreement in the assessment  
50 of muscle strength and functional abilities in Guillain-Barre syndrome. *Muscle Nerve*  
51 1991;14(11):1103-9.  
52  
53
- 54 25. Mathiowetz V, Weber K, Volland G, Kashman N. Reliability and validity of grip and  
55 pinch strength evaluations. *J Hand Surg Am* 1984;9(2):222-6.  
56  
57  
58  
59  
60

- 1  
2  
3 26. Mathiowetz V, Kashman N, Volland G, Weber K, Dowe M, Rogers S. Grip and pinch  
4 strength: normative data for adults. *Arch Phys Med Rehabil* 1985;66(2):69-74.  
5  
6 27. Zanni JM, Korupolu R, Fan E, Pradhan P, Janjua K, Palmer JB, et al. Rehabilitation  
7 therapy and outcomes in acute respiratory failure: an observational pilot project. *J Crit*  
8 *Care* 2010;25(2):254-62.  
9  
10 28. Nordon-Craft A, Schenkman M, Edbrooke L, Malone DJ, Moss M, Denehy L. The  
11 Physical Function Intensive Care Test: Implementation in Survivors of Critical Illness.  
12 *Phys Ther* 2014.  
13  
14 29. Denehy L, de Morton N, Skinner E, Edbrooke L, Haines K, Warrillow S, et al. A Physical  
15 Function Test for Use in the Intensive Care Unit: Validity, Responsiveness, and  
16 Predictive Utility of the Physical Function in Intensive Care Test (Scored). *Phys Ther*  
17 2013;93(12):1636-45.  
18  
19 30. Weiner DK, Duncan PW, Chandler J, Studenski SA. Functional reach: a marker of  
20 physical frailty. *J Am Geriatr Soc* 1992;40(3):203-7.  
21  
22 31. Newton RA. Validity of the multi-directional reach test: a practical measure for limits of  
23 stability in older adults. *J Gerontol A Biol Sci Med Sci* 2001;56(4):M248-52.  
24  
25 32. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al.  
26 The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive  
27 impairment. *J Am Geriatr Soc* 2005;53(4):695-9.  
28  
29 33. Ismail Z, Rajji TK, Shulman KI. Brief cognitive screening instruments: an update. *Int J*  
30 *Geriatr Psychiatry* 2010;25(2):111-20.  
31  
32 34. Holden MK, Gill KM, Magliozzi MR, Nathan J, Piehl-Baker L. Clinical gait assessment  
33 in the neurologically impaired. Reliability and meaningfulness. *Phys Ther*  
34 1984;64(1):35-40.  
35  
36 35. EuroQol-Group. EuroQol--a new facility for the measurement of health-related quality of  
37 life. *Health Policy* 1990;16(3):199-208.  
38  
39 36. Wood-Dauphinee SL, Opzoomer MA, Williams JI, Marchand B, Spitzer WO. Assessment  
40 of global function: The Reintegration to Normal Living Index. *Arch Phys Med Rehabil*  
41 1988;69(8):583-90.  
42  
43 37. Wood-Dauphinee S, Williams JI. Reintegration to Normal Living as a proxy to quality of  
44 life. *J Chronic Dis* 1987;40(6):491-502.  
45  
46 38. Salisbury LG, Merriweather JL, Walsh TS. Rehabilitation after critical illness: could a  
47 ward-based generic rehabilitation assistant promote recovery? *Nurs Crit Care*  
48 2010;15(2):57-65.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 39. van den Berg-Emons RJ, L'Ortye AA, Buffart LM, Nieuwenhuijsen C, Nooijen CF,  
4 Bergen MP, et al. Validation of the Physical Activity Scale for individuals with  
5 physical disabilities. *Arch Phys Med Rehabil* 2011;92(6):923-8.  
6  
7  
8 40. Armitage P, Colton T. *Encyclopedia of Biostatistics*. Chichester: Wiley, 1998.  
9  
10 41. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. *Journal of*  
11 *the American Statistical Association* 1958;53(282):457-481.  
12  
13 42. Kleinbaum D, Klein M. *Survival Analysis. A Self-Learning Text*. 3rd ed. New York:  
14 Springer, 2012.  
15  
16 43. Hosmer D, Lemeshow S, May S. *Applied Survival Analysis: Regression Modeling of Time*  
17 *to Event Data*. 2nd ed. New York: John Wiley & Sons, Inc., 2008.  
18  
19 44. Spiegelhalter DJ. Probabilistic prediction in patient management and clinical trials. *Stat*  
20 *Med* 1986;5(5):421-33.  
21  
22 45. Steyerberg EW, Eijkemans MJ, Harrell FE, Jr., Habbema JD. Prognostic modelling with  
23 logistic regression analysis: a comparison of selection and estimation methods in small  
24 data sets. *Stat Med* 2000;19(8):1059-79.  
25  
26 46. Hosmer DW, Lemeshow S. *Applied Logistic Regression*. 2ed ed. New York: John Wiley  
27 & Sons, Inc., 2000.  
28  
29 47. Schweickert WD, Pohlman MC, Pohlman AS, Nigos C, Pawlik AJ, Esbrook CL, et al.  
30  
31 Early physical and occupational therapy in mechanically ventilated, critically ill  
32 patients: a randomised controlled trial. *Lancet*, 2009:1874-82.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1** Summary of outcome measures and time points of assessment in GymNAST

	Baseline	Daily	Biweekly (T1 to T12)	Follow-up (FU 1 and 2)
<b>Amount and content of Physical Rehabilitation</b>				
Physiotherapy		x		x
Occupational Therapy		x		x
Other therapies (e.g. groups)		x		x
<b>Primary Outcome</b>				
FAC and STS	x	x		
<b>Delir measures</b>				
RASS	x		x	
<b>Strength measures</b>				
MRC score	x		x	x
Grip strength	x		x	x
<b>Physical function measures</b>				
PFIT and PFIT-S	x		x	x
FSS-ICU score	x		x	x
10m walking time	x		x	x
6-MWT	x		x	x
Pain (VAS)	x		x	x
functional reach	x		x	x
<b>Cognition measures</b>				
MOCA	x		x	x
CDT	x		x	x
<b>Activities and Mobility</b>				
BI	x		x	x
PASIPD				x
<b>Participation and quality of life</b>				
EQ-5D				x
RNL-Index				x

1  
2  
3 *Abbreviations:* GymNAST: General Weakness Syndrome Therapy study; FU= Follow Up; T=  
4 Time point; FAC: Functional Ambulation; STS: ability to stand up from a chair  
5 independently; RASS: Richmond Agitation-Sedation Scale; MRC: Medical Research Council  
6 (muscle strength of the upper (shoulder, elbow and wrist) and lower limb (hip, knee and  
7 ankle)); PFIT: Physical Function –Intensive Care Unit- Test; PFIT-S: Physical Function –  
8 Intensive Care Unit Test- Scored; FSS-ICU: Functional Status Score for the Intensive Care  
9 Unit Scored; 6-MWT: six minute walking test; VAS: visual analogue scale; MOCA=  
10 Montreal Cognitive Assessment; CDT: clock drawing test; BI: Barthel Index; PASIPD:  
11 Physical Activity Scale for Individuals with Physical Disabilities; EQ-5D: EuroQol (5  
12 dimensions); RNL-Index: Reintegration to Normal Living Index  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7 **The General Weakness Syndrome Therapy (GymNAST) study: protocol for a cohort**  
8 **study on recovery on walking function.**  
9

10 Jan Mehrholz<sup>1,3\*</sup>, Simone Mückel<sup>1</sup>, Frank Oehmichen<sup>2</sup> and Marcus Pohl<sup>2</sup>

11  
12 <sup>1</sup> *Wissenschaftliches Institut, Private Europäische Medizinische Akademie der Klinik Bavaria*  
13 *in Kreischa, An der Wolfsschlucht 1-2, 01731 Kreischa, Germany*

14  
15 <sup>2</sup> *Fach und Privatkrankenhaus, Klinik Bavaria in Kreischa, An der Wolfsschlucht 1-2, 01731*  
16 *Kreischa, Germany*

17  
18 <sup>3</sup> *Department of Public Health, Medizinische Fakultät, Carl Gustav Carus, Technische*  
19 *Universität Dresden, Germany*

20  
21  
22  
23 **\*Corresponding author**

24  
25 Prof. Dr. Jan Mehrholz, Wissenschaftliches Institut, Private Europäische Medizinische  
26 Akademie der Klinik Bavaria in Kreischa GmbH, An der Wolfsschlucht 1-2, 01731 Kreischa,  
27 Germany  
28

29  
30 Tel: ++49 35206 62054

31  
32 Fax: ++49 35206 63517

33  
34 [jan.mehrholz@klinik-bavaria.de](mailto:jan.mehrholz@klinik-bavaria.de)  
35

36  
37  
38 Short title: Study protocol: General Weakness Syndrome Therapy

39  
40  
41 Keywords: intensive care - rehabilitation - walking - muscle weakness  
42

43 **Word count: 4 623**

Formatted: Font: Bold

## Abstract

Introduction: Critical illness myopathy (CIM) and polyneuropathy (CIP) are common complications of critical illness that frequently occur together. Both cause so called intensive-care-unit-acquired (ICU)-acquired muscle weakness. This weakness of limb muscles increases morbidity and delay rehabilitation and recovery of walking ability. Although full recovery has been reported people with severe weakness may take months to improve walking. Focused physical rehabilitation of people with ICU-acquired muscle weakness is therefore of great importance.

However, although physical rehabilitation is common, detailed knowledge about the pattern and the time course of recovery of walking function are not well understood.

Therefore the aim of the General Weakness Syndrome Therapy (GymNAST) study is to describe the time course of recovery of walking function and other activities of daily living in these patients.

Methods and analysis: We conduct a prospective cohort study of people with ICU-acquired muscle weakness with defined diagnosis of CIM or CIP.

Based on our sample size calculation, approximately 150 patients will be recruited from the intensive care unit of our hospital in Germany. Amount and content of physical rehabilitation, clinical tests e.g. muscle strength and motor function and neuropsychological assessments will be used as independent variables. The primary outcomes will include recovery of walking function and mobility. Secondary outcomes will include global motor function, activities in daily life and participation.

Ethics and dissemination: The study is being carried out in agreement with the Declaration of Helsinki and conducted with the approval of the local medical Ethics Committee (Landesärztekammer Sachsen, Germany, reference number EK-BR-32/13-1) and with the understanding and written consent of each patient's guardian.

The results of this study will be published in peer-reviewed journals and disseminated to the medical society and general public.

## Article Summary

Article focus:

The aim of the General Weakness Syndrome Therapy (GymNAST) study is to determine the time course of recovery of walking function, to describe the detailed content of physical rehabilitation and also to describe possible risk factors and chances for recovery of walking function in the first year after ICU-acquired muscle weakness.

### Key messages:

This study will determine how people with ICU-acquired muscle weakness are related to clinical characteristics and describe the time course of motor and cognitive performance and activities of daily life.

The results will be of interest of clinicians working with critical ill patients and will give insights into the black box of rehabilitation and its impact on recovery of ICU-acquired muscle weakness due to CIM/CIP. The results of this study may therefore inform patients and their caregivers, therapists working in rehabilitation to choose the most appropriate treatment, and to develop adapted rehab programs.

### Strengths and limitations:

The strength of this study is that it is one of the first prospective cohort studies in the first year of ICU-acquired muscle weakness with daily documentation of physical rehabilitation and walking function. Multiple repeated assessments, with a wide range of clinical measures will be done. Such a measurement design has several advantages compared to other prognostic studies done so far using just two measurements in time. Our longitudinal repeated measure design may provide further insights into dynamics of recovery of walking function and other activities over the first year of people with ICU-acquired muscle weakness.

One limitation could be that most severe affected patients have to be excluded in this study. This may reduce the generalisability of the results to the whole population critical ill patients. Another limitation might be that no objective measures for muscle weakness such as electromyography or magnetic resonance tomography will be used.



## Introduction

Critical illness myopathy (CIM) and polyneuropathy (CIP) are common complications of critical illness that frequently occur together. Both cause so called intensive-care-unit-acquired (ICU)-acquired muscle weakness. According to Norton-Craft this weakness is characterized by a profound weakness that is greater than might be expected to result from prolonged bed rest [1]. The weakness of limb muscles limits significantly activities and assistance for basic activities such as sit-to stand or sitting and standing is oftentimes required [2-4]. This increases morbidity and delays rehabilitation and recovery of walking [5 6]. Although full recovery has been reported in approximately 50% of people with ICU-acquired muscle weakness, improvement is related to the severity of the condition e.g. people with severe weakness may take months to improve, or even remain severely affected [7 8]. Focused physical rehabilitation of people with ICU-acquired muscle weakness is therefore of great importance. There is practical evidence that physical rehabilitation of patients can be implemented with few adverse effects [1]. In recent years appropriate assessments were developed and description of suitable physical intervention strategies were described in the literature [1 8-12].

However, detailed knowledge about the time course of recovery of walking and other activities, their risk factors and chances for good recovery such are not well described or understood. Furthermore it lacks on detailed description of physical rehabilitation and on a repeated measure cohort study in the first year of people with ICU-acquired muscle weakness. Such a design would give better insights in to the time course of recovery of walking function and activities of these patients.

Therefore the aim of the General Weakness Syndrome Therapy (GymNAST) study is to describe and to identify time course and the pattern of recovery of walking, motor functions and of activities of daily living in these patients. Other aims are to describe the detailed content of physical rehabilitation and to develop a multivariate model of risk factors for recovery of walking function in the first year of ICU-acquired muscle weakness.

Here we describe the design and protocol of the GymNAST study, which is an appropriate large prospective cohort study of critical ill people with ICU-acquired muscle weakness including a detailed description of physical rehabilitation contents. This study will help to understand the time course and pattern of recovery of walking function and of activities of

1  
2  
3  
4  
5  
6  
7 daily live. Furthermore a multivariate model for recovery of walking ability will be  
8 developed.  
9

## 10 **Methods and analysis**

### 11 Study objectives

12  
13  
14 The primary objective of the GymNAST study is to assess the time course of regaining  
15 walking and sit to stand ability as important activities of daily live  
16

17 Secondary objectives are to:  
18

- 19 • describe the concomitant physical rehabilitation therapies
- 20
- 21 • describe the clinical course of recovery using standardized outcome measures and their
- 22 results
- 23
- 24 • identify a prognostic model for regain walking and sit to stand abilities
- 25
- 26
- 27
- 28
- 29

### 30 Design

31  
32 We conduct a prospective cohort study of people with ICU-acquired muscle weakness and  
33 defined diagnosis of CIM/CIP. We started in 2013 and the final assessments including follow  
34 up will be made in 2015.  
35

36  
37 Based on our sample size calculation [13 14], approximately 150 patients will be recruited  
38 from a intensive care unit of our hospital in Germany [15] over the time course of three years.  
39 In a first cross sectional pilot study in our hospital we found a point prevalence of 88 patients  
40 with defined diagnosis of CIM/CIP and ICU-acquired muscle weakness per month [16].  
41 Therefore, based on this pilot study it seems to be realistically to reach the anticipated sample  
42 size in our cohort study within three years of recruitment.  
43  
44  
45

### 46 Study population

47  
48 Patients with ICU-acquired muscle weakness and defined diagnosis of CIM/CIP will be  
49 recruited consecutively from the intensive care units of our acute care, weaning and early  
50 rehabilitation centers of Klinik Bavaria Kreischa in Germany.  
51  
52

### 53 Inclusion criteria

- patient is chronic critical ill **or has a contemporary history of chronic critical ill defined as more than 21 days ICU-treatment including mechanical ventilation and at least 14 days further existing critical situation with the need for ICU-treatment [17]**

Formatted: Font: Bold

Formatted: Font: Bold

Formatted: Font: Bold

- defined diagnosis of Critical illness myopathy (CIM) and polyneuropathy (CIP). **The diagnosis of CIM/CIP will be confirmed by a neurologist. Therefore, clinical and neurophysiologic data will be revealed. The procedure of diagnosis of CIP and CIM is described in detail elsewhere [18-20]**

Formatted: Font: Bold

Formatted: Font: Bold

Formatted: Font: Bold

- muscle weakness defined as a Medical Research Council (MRC) sum score of less than 48 points [1]
- more than 18 years old
- Richmond Agitation Sedation Scale (RASS) score from -1 to 2 [21]
- written informed consent of the patient or his legal guardian

#### Exclusion criteria

- Patients receiving palliative care
- Co-morbidities of the trunk or the lower limbs interfering with upright posture and walking function (e.g. Amputation or fracture of lower limb)
- Other neuromuscular or neurological disease **and/or syndromes causing weakness in patients in the ICU (we will exclude patients with diseases and syndromes causing weakness in patients in the ICU[8], due to Guillain–Barré syndrome, myasthenia gravis, porphyria, Eaton–Lambert syndrome, amyotrophic lateral sclerosis, vasculitic neuropathy, cervical myelopathy and botulism)**
- severe physical co-morbidity before becoming critical ill (e.g. frailty due to neurological conditions)

#### Procedure

Eligible patients will be screened and afterwards will get oral and written information about the study from their treating physician or researcher. After written informed consent the

1  
2  
3  
4  
5  
6  
7 demographic and clinical characteristics will be measured (baseline assessment T0). Patients  
8 will then be measured every two weeks after baseline up to 20 weeks (week two (T1), week  
9 four (T2), week six (T3), week eight (T4) week ten (T5) and so on until week twenty (T10)).  
10 Two follow ups are planned: FU1 after six month and FU2 after one year after study entry.  
11 For follow-up assessments (FU1 and FU2), patients and their guardians will be informed and  
12 invited by letter and telephone to participate.  
13  
14

15  
16 The amount and the content of physical rehabilitation, activities of daily life such as the  
17 ability to walk will be documented every day by physiotherapists and occupational therapist  
18 using predefined sheets [16]. All assessments and standardized measures will be administered  
19 by trained and experienced assessors or therapists in the hospital and/or inpatient  
20 rehabilitation, at home or residence facility. **Additionally, we will try to get all information**  
21 **about the content and duration of physiotherapy and or physical rehabilitation applied at all**  
22 **stages of illness.**  
23  
24  
25  
26  
27

### 28 Measures and Outcomes

29  
30 Primary outcomes of the GYMNAST study are walking ability and ability to stand up alone.

31  
32 To measure walking ability the Functional Ambulation Categories (FAC) is used [22]. The  
33 ability to stand up alone will be measured by the ability to stand up from a chair  
34 independently, STS (standardised chair height is defined with 120% of knee height).  
35  
36  
37

38 Secondary outcomes includes

- 39 • Richmond Agitation-Sedation Scale (RASS) [21]
  - 40 • activities measured with the Barthel Index (BI; 10 items) [23]
  - 41 • muscle strength of the upper (shoulder, elbow and wrist) and lower limb (hip, knee  
42 and ankle) using the Medical Research Council (MRC) [1 24]
  - 43 • grip strength (measured bilaterally using a dynamometer) [25 26]
  - 44 • Functional Status Score for the Intensive Care Unit Scored (FSS-ICU) [27]
  - 45 • Physical Function –ICU Test (PFIT) [28] and Physical Function –ICU Test- Scored  
46 (PFIT-S) [29]
- 47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1
- 2
- 3
- 4
- 5
- 6
- 7 • Pain using a visual analogue scale
- 8
- 9 • Lateral and frontal sit and stance balance (functional reach) [30 31]
- 10
- 11 • cognitive measures (Montreal Cognitive Assessment (MoCA) [32] and clock drawing
- 12 test (CDT) [33]
- 13
- 14 • walking ability (0- 5; FAC) [34], walking speed (we will use a 10m walking test,
- 15 adopting a 14-m course and will measure the walking speed over the central 10 m)
- 16 and walking endurance (we will use a six minute walking test, using 40m course and
- 17 will measure the distance walked in six minutes; if patients cannot walk the whole six
- 18 minutes we will measure the maximum walking distance here) [5 6]
- 19
- 20
- 21
- 22 • quality of life (EQ-5D) [35]
- 23
- 24 • participation (Reintegration to Normal Living, RNL-Index) [36 37]
- 25
- 26
- 27 • fitness and mobility (PASIPD) [38 39]
- 28

29 All measures chosen are frequently used in research and/or daily clinical practice dealing with  
30 the above described patients.

31  
32  
33 The primary outcome variables FAC and STS will be measured daily with standardized sheets  
34 for this purpose.

35  
36 At baseline assessment (T0) and then every two weeks until twenty weeks after baseline  
37 (T10) we will assess RASS, BI, muscle strength of the upper and lower limb (MRC), grip  
38 strength, FSS-ICU, PFIT and PFIT-S, pain, functional reach, cognitive measures, walking  
39 speed and endurance.

40  
41  
42 At follow ups FU1 after six month and FU2 after one year after study entry we will measure  
43 the EQ-5D, the RNL-Index and PASIPD. Additionally we will be gathering detailed survival  
44 data.

45  
46  
47 Tables 1 gives a detailed overview of the variables used at each time point of study.

#### 48 49 50 51 52 Possible clinical prognostic factors

1  
2  
3  
4  
5  
6  
7 Depending on the primary outcomes (walking ability and activities), a range of potentially  
8 prognostic factors will be taken into account. These factors include: demographic variables  
9 (such as age, sex), clinical variables (such as FSS-ICU, PFIT-S) and medical characteristics  
10 (such as **diagnoses, reason for ICU-treatment, duration of mechanical ventilation, duration of**  
11 **illness) and anthropometric measures, such as body weight and body mass index (but not limb**  
12 **circumference).**  
13  
14

### 15 16 17 18 Planned statistical analyses 19

20 We will use descriptive analyses, e.g. means and standard deviations of the continuous  
21 variables and frequencies and proportions of categorical variables as appropriate [40]. We will  
22 explain differences across the time points (T1–T10 and FU1 - FU2) descriptively and with  
23 appropriate inference statistics use parametric and non-parametric tests as appropriate e.g.  
24 repeated measures analysis of variance [40]. The global alpha level will be set at 0.05.  
25  
26

27 Time to regain walking ability and time to stand up from a chair independently will be the  
28 main end point for this analysis. The following factors will be analyzed for their association  
29 with these endpoints:  
30  
31

- 32 • demographic variables (such as age and sex),
- 33 • clinical variables (such as muscle strength, FSS-ICU, PFIT-S) and
- 34 • medical characteristics (such as diagnosis and duration of illness)
- 35
- 36
- 37
- 38
- 39

40 The probability in regaining walking ability and sit to stand ability will be calculated with the  
41 method of Kaplan and Meier [41]. Cox regression analysis will be used to estimate relative  
42 hazard rates and to test for differences in variables or trends in subgroups of each factor [42].  
43 A stepwise multivariable Cox regression analysis will be applied with a variable selection [42  
44 43].  
45  
46

47 Time to event or censoring will be defined as time difference between study entry (T0) and  
48 date of reaching a FAC score equal to 3, or the possible censoring dates of discharge or dead,  
49 respectively. Possible prognostic factors from demographic, clinical and medical variables  
50 will be selected for a multivariable model based on clinical and statistical significance [44-  
51 46]. The final model selection will be performed based on clinical decision, together with  
52 Akaike's information criterion (AIC) and the Bayesian information criterion (BIC) [43]. Aim  
53  
54  
55  
56  
57  
58  
59  
60

of our analysis is to *explain* the dependent variable (regaining walking function) by a multivariate Cox proportional hazard model with not too many variables.

To prevent overfitting, only variables with clinically important *and* statistically significant bivariate association with our endpoint will be included in the final model [43].

The effects of prognostic factors in the final model will be expressed as hazard ratios (HR) with 95% confidence intervals (CI) after a graphical assessment of proportionality of hazards.

We will use SAS/STAT 9.3 for all statistical procedures (SAS Institute Inc., Cary, NC, USA).

The proportional hazards assumption will be tested with the implemented function (proc phreg).

## Results

We will describe the demographic and clinical characteristics at each of the individual time points (T1–T10 and FU1 - FU2) descriptively. We will describe the probability in regaining walking ability and other activities with the method of Kaplan and Meier. We will present the final statistical multivariate model for regaining walking ability.

### Sample size and power calculation

The sample size needed in the GymNAST study is calculated using the method for one of the most cited recommendation for prognostic research: the ‘rule of ten events per variable (EPV)’ [13 14 46]. Based on our sample size calculation using the EPV-approach approximately 150 patients will be recruited from the intensive care unit of our long term intensive care hospital in Germany [15]. We anticipate reaching this study size over the time course of three years. Our confidence results from a cross-sectional study. We found a point prevalence of 88 patients per month of people with ICU-acquired muscle weakness and defined diagnosis of CIM/CIP in our intensive care units [16]. Therefore, based on this pilot study it seems to be a realistically to reach the estimated sample size in our cohort study within three years of recruitment.

## **Ethics and Dissemination**

### Ethical considerations

1  
2  
3  
4  
5  
6  
7 The GymNAST study will be conducted in accordance with the 'Helsinki Declaration'. The  
8 study is non-invasive, imposes no risk on patients, seems to have enough power to detect  
9 meaningful determinants and our protocol has been approved by the medical ethical  
10 committees. Furthermore, written informed consent is obtained from all participants or if  
11 necessary from its legal guardian. The study will be registered before publication.  
12  
13

#### 14 Dissemination

15  
16 The results obtained will be disseminated to the scientific, medical and general public by  
17 publication in national and international peer-reviewed journals, as well as by presentations in  
18 conferences and meetings with clinicians dealing with patients with ICU-acquired muscle  
19 weakness syndrome.  
20  
21  
22  
23  
24

#### 25 **Discussion**

26  
27 The GymNAST study will be one of the first studies with rigorous repeated measures over the  
28 time course of one year with daily documentation of rehabilitation therapies of people with  
29 ICU-acquired muscle weakness. Also a wide range of functional variables to describe the  
30 pattern of regaining of walking is used.  
31  
32  
33

34 Until now many prognostic studies including people with ICU-acquired muscle weakness  
35 used rather a traditional prognostic design using a baseline test and compared with ICU  
36 discharge and follow-ups [5 28 29] and only some studies measures continuously over time  
37 [47]. However, instead of comparing two or more measurements of the patient's performance  
38 it seems to be more informative to analyze the dynamic recovery systematically using equal  
39 time intervals over an appropriate time period e.g. with daily assessments of walking function  
40 and with daily description of physical rehabilitation over months. This might provide a more  
41 detailed understanding of the pattern and the dynamics of recovery of walking function, and  
42 allows a better understanding of changes in clinical characteristics and the applied  
43 rehabilitation therapies.  
44  
45  
46  
47  
48

49 Also, detailed knowledge about the time course of recovery of walking ability, their risks and  
50 chances (e.g. clinical and therapeutic determinants) are still not very well understood. The  
51 present study documents clinical determinants at equal time intervals (every two weeks) and  
52 will document therapeutic determinants daily.  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Strong aspects of GymNAST are therefore its prospective design with multiple repeated assessments during the first year after illness using equal time intervals of people with ICU-acquired muscle weakness. The present study might therefore provide new and more detailed information about the pattern of walking recovery and the physical rehabilitation content of people with ICU-acquired muscle weakness.

A potential limitation of the study is that the most seriously affected patients might be unable to participate, thereby reducing the possibility to generalize the results to the whole critical ill population. Another limitation might be that no objective measures for muscle weakness such as electromyography or magnetic resonance tomography will be used.

**Authors' contributions:**

J.M., S.M, FO and M.P. planned the study. F.O. and M.P. contributed to the procurement of funding. J.M., S.M, and M.P. developed the protocol. All authors contributed to and checked the final draft of the manuscript.

**Funding statement:**

This study is financially supported by the Centre of Research from Klinik Bavaria, Kreischa, Germany and by the Department of Public Health, Medizinische Fakultät ,Carl Gustav Carus', Technische Universität Dresden, Germany

**Competing interests statement:**

None declared

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60**Literatur**

1. Nordon-Craft A, Moss M, Quan D, Schenkman M. Intensive Care Unit-Acquired Weakness. *Phys Ther* 2012;92(12):1494-506.
2. Fan E. Critical illness neuromyopathy and the role of physical therapy and rehabilitation in critically ill patients. *Respir Care* 2012;57(6):933-44; discussion 944-6.
3. Herridge MS. The challenge of designing a post-critical illness rehabilitation intervention. *Crit Care* 2011;15(5):1002.
4. Ohtake PJ, Strasser DC, Needham DM. Rehabilitation for people with critical illness: taking the next steps. *Physical Therapy* 2012;92(12):1484-8.
5. Herridge MS, Cheung AM, Tansey CM, Matte-Martyn A, Diaz-Granados N, Al-Saidi F, et al. One-year outcomes in survivors of the acute respiratory distress syndrome. *N Engl J Med* 2003;348(8):683-93.
6. Herridge MS, Tansey CM, Matte A, Tomlinson G, Diaz-Granados N, Cooper A, et al. Functional disability 5 years after acute respiratory distress syndrome. *N Engl J Med* 2011;364(14):1293-304.
7. Hermans G, De Jonghe B, Bruyninckx F, Van den Berghe G. Clinical review: critical illness polyneuropathy and myopathy. *Critical Care*, 2008:238.
8. Kress J, Hall J. ICU-acquired weakness and recovery from critical illness. *N Engl J Med* 2014;370(17):1626-35.
9. Denehy L, Berney S, Skinner E, Edbrook L, Warrillow S, Hawthorne G, et al. Evaluation of Exercise Rehabilitation for Survivors of Intensive Care: Protocol for Single Blind Randomised Controlled Trial. *The Open Critical Care Medicine Journal* 2008;1:39-47.
10. Denehy L, Berney S, Skinner E, Edbrooke L, Warrillow S, Hawthorne G, et al. Evaluation of exercise rehabilitation for survivors of intensive care: protocol for single blind randomised controlled trial. *Open Critical Care Medicine Journal*, 2008:39-47.
11. Denehy L, Skinner EH, Edbrooke L, Haines K, Warrillow S, Hawthorne G, et al. Exercise rehabilitation for patients with critical illness: a randomized controlled trial with 12 months follow up. *Crit Care* 2013;17(4):R156.
12. Nordon-Craft A, Schenkman M, Ridgeway K, Benson A, Moss M. Physical therapy management and patient outcomes following ICU-acquired weakness: a case series. *J Neurol Phys Ther* 2011;35(3):133-40.
13. Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. *J Clin Epidemiol* 1995;48(12):1503-10.
14. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. *Am J Epidemiol* 2007;165(6):710-8.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
15. Mallett S, Royston P, Dutton S, Waters R, Altman DG. Reporting methods in studies developing prognostic models in cancer: a review. *BMC Med* 2010;8:20.
16. Mückel S, Mehrholz K, Mehrholz J, Pohl M. Treatment approaches of patients with ICU acquired weakness [Behandlungsansätze bei Patienten mit auf der Intensivstation erworbenen Schwächesyndrom]. *Neuroreha* 2013;5(1):40-43.
17. **Oehmichen F, Ragaller M. Beatmungsentwöhnung bei Chronisch-Kritisch-Kranken. Intensiv- und Notfallbehandlung 2012;37(3):118-126.**
18. **Oehmichen F, Pohl M, Schlosser R, Stogowski D, Toppel D, Mehrholz J. Critical-illness-Polyneuropathie und -Polymyopathie. Wie sicher ist die klinische Diagnose bei Patienten mit Weaning-Versagen? [Critical illness polyneuropathy und polymyopathy : How certain is the clinical diagnosis in patients with weaning failure?]. *Nervenarzt* 2012;83(2):220-225.**
19. Latronico N, Rasulo FA. Presentation and management of ICU myopathy and neuropathy. *Curr Opin Crit Care* 2010;16(2):123-7.
20. Latronico N, Bolton C. Critical illness polyneuropathy and myopathy: a major cause of muscle weakness and paralysis. *Lancet Neurology* 2011;10(10):931-41.
21. Sessler CN, Gosnell MS, Grap MJ, Brophy GM, O'Neal PV, Keane KA, et al. The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients. *Am J Respir Crit Care Med* 2002;166(10):1338-44.
22. Holden MK, Gill KM, Magliozzi MR. Gait assessment for neurologically impaired patients. Standards for outcome assessment. *Phys Ther* 1986;66(10):1530-9.
23. Mahoney FI, Barthel DW. Functional Evaluation: The Barthel Index. *Md State Med J* 1965;14:61-5.
24. Kleyweg RP, van der Meche FG, Schmitz PI. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barre syndrome. *Muscle Nerve* 1991;14(11):1103-9.
25. Mathiowetz V, Weber K, Volland G, Kashman N. Reliability and validity of grip and pinch strength evaluations. *J Hand Surg Am* 1984;9(2):222-6.
26. Mathiowetz V, Kashman N, Volland G, Weber K, Dowe M, Rogers S. Grip and pinch strength: normative data for adults. *Arch Phys Med Rehabil* 1985;66(2):69-74.
27. Zanni JM, Korupolu R, Fan E, Pradhan P, Janjua K, Palmer JB, et al. Rehabilitation therapy and outcomes in acute respiratory failure: an observational pilot project. *J Crit Care* 2010;25(2):254-62.
28. Nordon-Craft A, Schenkman M, Edbrooke L, Malone DJ, Moss M, Denehy L. The Physical Function Intensive Care Test: Implementation in Survivors of Critical Illness. *Phys Ther* 2014.
29. Denehy L, de Morton N, Skinner E, Edbrooke L, Haines K, Warrillow S, et al. A Physical Function Test for Use in the Intensive Care Unit: Validity, Responsiveness, and Predictive

Formatted: Font: Bold, Font color: Blue

- 1  
2  
3  
4  
5  
6 Utility of the Physical Function in Intensive Care Test (Scored). *Phys Ther* 2013;93(12):1636-  
7 45.  
8  
9 30. Weiner DK, Duncan PW, Chandler J, Studenski SA. Functional reach: a marker of physical frailty.  
10 *J Am Geriatr Soc* 1992;40(3):203-7.  
11  
12 31. Newton RA. Validity of the multi-directional reach test: a practical measure for limits of stability  
13 in older adults. *J Gerontol A Biol Sci Med Sci* 2001;56(4):M248-52.  
14  
15 32. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. The  
16 Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment.  
17 *J Am Geriatr Soc* 2005;53(4):695-9.  
18  
19 33. Ismail Z, Rajji TK, Shulman KI. Brief cognitive screening instruments: an update. *Int J Geriatr*  
20 *Psychiatry* 2010;25(2):111-20.  
21  
22 34. Holden MK, Gill KM, Magliozzi MR, Nathan J, Piehl-Baker L. Clinical gait assessment in the  
23 neurologically impaired. Reliability and meaningfulness. *Phys Ther* 1984;64(1):35-40.  
24  
25 35. EuroQol-Group. EuroQol--a new facility for the measurement of health-related quality of life.  
26 *Health Policy* 1990;16(3):199-208.  
27  
28 36. Wood-Dauphinee SL, Opzoomer MA, Williams JI, Marchand B, Spitzer WO. Assessment of  
29 global function: The Reintegration to Normal Living Index. *Arch Phys Med Rehabil*  
30 1988;69(8):583-90.  
31  
32 37. Wood-Dauphinee S, Williams JI. Reintegration to Normal Living as a proxy to quality of life. *J*  
33 *Chronic Dis* 1987;40(6):491-502.  
34  
35 38. Salisbury LG, Merriweather JL, Walsh TS. Rehabilitation after critical illness: could a ward-based  
36 generic rehabilitation assistant promote recovery? *Nurs Crit Care* 2010;15(2):57-65.  
37  
38 39. van den Berg-Emons RJ, L'Ortye AA, Buffart LM, Nieuwenhuijsen C, Nooijen CF, Bergen MP, et  
39 al. Validation of the Physical Activity Scale for individuals with physical disabilities. *Arch*  
40 *Phys Med Rehabil* 2011;92(6):923-8.  
41  
42 40. Armitage P, Colton T. *Encyclopedia of Biostatistics*. Chichester: Wiley, 1998.  
43  
44 41. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. *Journal of the*  
45 *American Statistical Association* 1958;53(282):457-481.  
46  
47 42. Kleinbaum D, Klein M. *Survival Analysis. A Self-Learning Text*. 3rd ed. New York: Springer,  
48 2012.  
49  
50 43. Hosmer D, Lemeshow S, May S. *Applied Survival Analysis: Regression Modeling of Time to*  
51 *Event Data*. 2nd ed. New York: John Wiley & Sons, Inc., 2008.  
52  
53 44. Spiegelhalter DJ. Probabilistic prediction in patient management and clinical trials. *Stat Med*  
54 1986;5(5):421-33.  
55  
56 45. Steyerberg EW, Eijkemans MJ, Harrell FE, Jr., Habbema JD. Prognostic modelling with logistic  
57 regression analysis: a comparison of selection and estimation methods in small data sets. *Stat*  
58 *Med* 2000;19(8):1059-79.  
59  
60

- 1  
2  
3  
4  
5  
6  
7 46. Hosmer DW, Lemeshow S. *Applied Logistic Regression*. 2ed ed. New York: John Wiley & Sons,  
8 Inc., 2000.
- 9 47. Schweickert WD, Pohlman MC, Pohlman AS, Nigos C, Pawlik AJ, Esbrook CL, et al. Early  
10 physical and occupational therapy in mechanically ventilated, critically ill patients: a  
11 randomised controlled trial. *Lancet*, 2009:1874-82.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1** Summary of outcome measures and time points of assessment in GymNAST

	Baseline	Daily	Biweekly (T1 to T12)	Follow-up (FU 1 and 2)
<b>Amount and content of Physical Rehabilitation</b>				
Physiotherapy		x		x
Occupational Therapy		x		x
Other therapies (e.g. groups)		x		x
<b>Primary Outcome</b>				
FAC and STS	x	x		
<b>Delir measures</b>				
RASS	x		x	
<b>Strength measures</b>				
MRC score	x		x	x
Grip strength	x		x	x
<b>Physical function measures</b>				
PFIT and PFIT-S	x		x	x
FSS-ICU score	x		x	x
10m walking time	x		x	x
6-MWT	x		x	x
Pain (VAS)	x		x	x
functional reach	x		x	x
<b>Cognition measures</b>				
MOCA	x		x	x
CDT	x		x	x
<b>Activities and Mobility</b>				
BI	x		x	x
PASIPD				x
<b>Participation and quality of life</b>				
EQ-5D				x
RNL-Index				x

1  
2  
3  
4  
5  
6  
7 *Abbreviations:* GymNAST: General Weakness Syndrome Therapy study; FU= Follow Up; T=  
8 Time point; FAC: Functional Ambulation; STS: ability to stand up from a chair  
9 independently; RASS: Richmond Agitation-Sedation Scale; MRC: Medical Research Council  
10 (muscle strength of the upper (shoulder, elbow and wrist) and lower limb (hip, knee and  
11 ankle)); PFIT: Physical Function –Intensive Care Unit- Test; PFIT-S: Physical Function –  
12 Intensive Care Unit Test- Scored; FSS-ICU: Functional Status Score for the Intensive Care  
13 Unit Scored; 6-MWT: six minute walking test; VAS: visual analogue scale; MOCA=  
14 Montreal Cognitive Assessment; CDT: clock drawing test; BI: Barthel Index; PASIPD:  
15 Physical Activity Scale for Individuals with Physical Disabilities; EQ-5D: EuroQol (5  
16 dimensions); RNL-Index: Reintegration to Normal Living Index  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60